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Abstract 
Tissue-Specific effects of Pregnane X Receptor (PXR) and Estrogen Sulfotransferase (EST) 
on Hemorrhagic Shock-Induced Multiple Organ Injuries 
 
Yang Xie, PhD 
 
University of Pittsburgh, 2020 
 
 
Hemorrhagic shock (HS) is a life-threatening condition associated with tissue 
hypoperfusion. HS may lead to dysfunction of multiple organs, including the liver and lung, as a 
result of oxidative stress and a secondary inflammatory stimulus. Pregnane X receptor (PXR) is a 
species-specific xenobiotic receptor that regulates the expression of drug-metabolizing enzymes 
(DMEs) such as the cytochrome P450 3A (CYP3A). Many clinical drugs, including those often 
prescribed to trauma patients, are known to activate PXR and induce CYP3A. However, it is 
unclear whether and how PXR plays a role in the regulation of DMEs in the setting of HS and HS-
induced hepatic and extrahepatic injury. The estrogen sulfotransferase (EST, or SULT1E1) is a 
conjugating enzyme that sulfonates and deactivates estrogens. We have previously reported that 
the expression of EST is highly inducible in the livers of mouse models of multiple diseases, 
including obesity and type 2 diabetes, liver ischemia and reperfusion, and sepsis. The induction of 
EST by these disease conditions led to attenuated estrogen responses and have impact on the 
outcome of these diseases through varied mechanisms and often in a sex- and tissue-specific 
manner. It is unclear whether and how EST plays a role in HS-induced liver and lung injury. In 
this dissertation study, I studied the tissue-specific effects of PXR and EST on HS-induced hepatic 
injury and acute lung injury, respectively. My results demonstrated that (1) activation of PXR 
sensitizes mice to HS-induced hepatic injury but not acute lung injury. The unavoidable use of 
PXR-activating drugs in trauma patients has the potential to exacerbate HS-induced hepatic injury, 
which can be mitigated by the co-administration of anti-oxidative agents, CYP3A inhibitors, or 
 v 
PXR antagonists. (2) Genetic ablation or pharmacological inhibition of Est effectively protected 
female mice from HS-induced acute lung injury. The pulmonoprotective effect of Est ablation or 
inhibition was sex- and tissue-specific. HS-induced hepatic injury was not affected in Est knockout 
(Est-/-) mice. Pharmacological inhibition of EST may represent an effective approach in female 
patients to manage HS-induced acute lung injury. In summary, my dissertation research has 
uncovered the tissue-specific effects of PXR and EST on HS-induced multiple organ injuries.  
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1.0 Introduction 
Hemorrhagic shock (HS), a life-threatening condition when the body loses more than 20% 
of its blood or fluid supply, is the leading cause of death and disability in patients younger than 54 
years of age (Krug et al., 2000). During the acute phase of hemorrhage, in addition to stopping 
bleeding, fluid resuscitation is a therapeutic priority in the clinic. Although the modern 
resuscitation techniques developed in the 1960s have led to an improved immediate survival, the 
emergence of subsequent organ failure remains a major health issue that may lead to late death 
(Minei et al., 2012). Among the mechanisms of HS-induced tissue injury, an exaggerated 
inflammatory response and oxidative stress generated through resuscitation are the major 
contributors to cellular membrane damage, cell death and tissue damage (Toklu and Tumer, 2015). 
The liver (Yu et al., 2008; Wetzel et al., 2014) and lung (Rubenfeld et al., 2005; Villar et al., 2014) 
are organs sensitive to HS-induced injury. A growing body of evidence has also put the xenobiotic 
receptors, such as PXR, and metabolic enzymes, such as EST, in the physiological and 
pathological context beyond the classical functions, such as endobiotic metabolism and immune 
responses. These newest findings propel us to do further investigation on the novel functions of 
PXR and EST in the underlying molecular mechanisms of HS-induced multiple organ injuries. 
1.1 Hypothesis and Specific Aims  
Studies by others have suggested that PXR and EST play fundamental roles in exogenous 
and endogenous metabolism, which impact on multiple diseases, including drug-induced liver 
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injury, obesity and type 2 diabetes, hepatic ischemia and reperfusion, and sepsis. The dissertation 
work was dedicating to the novel hepatic/extrahepatic function of PXR and EST in HS-induced 
multiple organ injures. The overall hypothesis is that 1) activation of PXR sensitizes hemorrhagic 
shock-induced liver injury via inducing the expression of CYP3A and oxidative stress, but shows 
no effects on HS-induced acute lung injury; 2) hepatic EST distantly sensitizes mice to HS-induced 
acute lung injury in a sex-specific manner, but shows very limited impact on HS-induced hepatic 
injury.  
There are two specific aims in the dissertation study: 
For the specific Aim 1, we have investigated the role of PXR in the regulation of drug 
metabolism enzymes (DMEs) in the setting of HS, and whether activation of PXR is beneficial or 
detrimental to HS-induced hepatic injury. PXR transgenic, knockout, and humanized mice were 
subject to hemorrhagic shock and resuscitation (HS/R). The liver injury, as well as lung injury, 
was assessed histologically and biochemically. The expression and/or activity of PXR and CYP3A 
were manipulated genetically or pharmacologically in order to determine their effects on HS-
induced hepatic injury. Our results showed that genetic or pharmacological activation of PXR 
sensitized wild-type (WT) and hPXR/CYP3A4 humanized mice to HS-induced hepatic injury, 
whereas knockout of PXR protected mice from HS-induced hepatic injury. The manipulation of 
PXR showed little impact on HS-induced acute lung injury which can be explained by the low 
expression of PXR in the lung. Mechanistically, the sensitizing effect on liver injury of PXR 
activation was accounted for by PXR-responsive induction of CYP3A and increased oxidative 
stress in the liver. The sensitizing effect of PXR was attenuated by ablation or pharmacological 
inhibition of CYP3A, treatment with the antioxidant N-acetylcysteine amide (NACA), or treatment 
with a PXR antagonist. In this specific study, we have uncovered a novel function of PXR in HS-
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induced hepatic injury. Our results suggest that the unavoidable use of PXR-activating drugs in 
trauma patients has the potential to exacerbate HS-induced hepatic injury, which can be mitigated 
by the co-administration of anti-oxidative agents, CYP3A inhibitors, or PXR antagonists. 
 
For the specific Aim 2, we have investigated the role of liver EST in HS-induced acute 
lung injury through sulfonating and deactivating estrogens. In this specific study, we showed that 
the expression of Est was markedly induced in the liver, but not in the lung of female mice subject 
to HS/R. Genetic ablation or pharmacological inhibition of Est effectively protected female mice 
from HS-induced acute lung injury, including interstitial edema, neutrophil mobilization and 
infiltration, and inflammation, while showed limited protection from HS-induced hepatic injury. 
The pulmonoprotective effect Est ablation or inhibition was sex-specific, because the HS-induced 
acute lung injury was not affected in male Est-/- mice. Mechanistically, the pulmonoprotective 
phenotype in female Est-/- mice was accompanied by increased lung and circulating levels of 
estrogens, attenuated pulmonary inflammation, and inhibition of neutrophil mobilization from the 
bone marrow and infiltration to the lung, whereas the pulmonoprotective effect was abolished upon 
ovariectomy, suggesting that the pulmonoprotective effect was estrogen dependent. The 
pulmonoprotective effect of Est ablation was also tissue-specific, as loss of Est had little effect on 
HS-induced hepatic injury. Moreover, transgenic reconstitution of human EST in the liver of 
global Est-/- mice abolished the pulmonoprotective effect, suggesting that it is the EST in the liver 
that contributes to HS-induced acute lung injury. Taken together, our results revealed a sex- and 
tissue-specific role of EST in HS-induced acute lung injury. Pharmacological inhibition of EST 
may represent an effective approach in female patients to manage HS-induced acute lung injury. 
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1.2 Dissertation Outline 
The contents of the dissertation include:  
Chapter I. Introduction (this chapter) is a concise description of the dissertation, 
including research background, overall research hypothesis, and specific aims with general 
research approaches.  
Chapter II. Pregnane X receptor and hemorrhagic shock-induced hepatic injury is a 
complete research report for the specific Aim 1 that describes the study background, 
methodology, experimental results, and discussion and conclusion.   
Chapter III. Estrogen sulfotransferase and hemorrhagic shock-induced acute lung 
injury includes literature review of estrogen sulfotransferases in liver diseases and a complete 
research report for the specific Aim 2 that describes the study background, methodology, 
experimental results, and discussion and conclusion.  
Chapter IV. Summary is a conclusive overview for the sex- and tissue-specific role of 
PXR and EST in the hemorrhagic shock-induced multiple organ injuries, including liver and lung. 
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2.0 Pregnane X receptor and hemorrhagic shock-induced hepatic injury 
2.1 Research Background 
Hemorrhagic shock (HS), a life-threatening condition when the body loses more than 20% 
of its blood or fluid supply, is the leading cause of death and disability in patients younger than 54 
years of age (Krug et al., 2000). During the acute phase of hemorrhage, in addition to stopping 
bleeding, fluid resuscitation is a therapeutic priority in the clinic. Although the modern 
resuscitation techniques developed in the 1960s have led to an improved immediate survival, the 
emergence of subsequent organ failure remains a major health issue that may lead to late death 
(Minei et al., 2012). The pathogenesis of HS-induced tissue injury is dynamic, including the 
hypoperfusion and hypoxia resulted from deprivation of blood supply during acute phase and 
oxidative stress introduced during the restoration of blood volume upon resuscitation (Figure 1). 
The free radicals generated through oxidative stress leads to cellular membrane damage and cell 
death and trigger secondary tissue and organ injury (Toklu and Tumer, 2015). The liver is an organ 
sensitive to HS-induced injury (Yu et al., 2008; Wetzel et al., 2014). In the liver, the cytochrome 
P450 (CYP) enzymes in the hepatocytes represent an important source of reactive oxygen species 
(ROS), which may lead to mitochondrial dysfunction and cell necrosis upon HS (Jaeschke, 2011; 
Tsai et al., 2015; Logsdon et al., 2016). CYP3A is the most abundant hepatic P450. Although the 
effect of CYP3A on ROS generation might be substrate dependent, it is believed that CYP3A plays 
a major role in the overall ability of the human liver to generate ROS (Puntarulo and Cederbaum, 
1998).  
 6 
 
Figure 1. Pathogeneis of Hemorrhagic Shock. 
Pregnane X receptor (PXR) is a species specific xenobiotic receptor that regulates the 
expression of drug-metabolizing enzymes (DEMs) with CYP3A as its primary target gene (Yan 
and Xie, 2016). Like other nuclear receptors, PXR is characterized by ligand binding domain and 
and DNA binding domain. It can be activated by a range of endogenous and exogenouse 
compounds, such as pregnanes, progesterone, corticosterone, testosterone, lithocholic acids, and 
the steroid-like xenobiotic dexamethasone (Xue et al., 2007). Upon activation, PXR would form a 
heterodimer with retinoid X receptor (RXR) and bind to the responsive element in the promoter 
area of regulated genes (Xie et al., 2000b; Willson and Kliewer, 2002). 
Seriously injured trauma patients are uniformly prescribed with multiple medications, 
including common ICU medications, such as fentanyl, protonix, dexamethasone (DEX) 
(Grinstein-Nadler and Bottoms, 1976; Zingarelli et al., 1994), benzodiazepines (Abel and Reis, 
1971), and other medications, such as Tylenol and oxycodone for post-surgery pain management, 
statins and fibrates for trauma patients with hyperlipidemia, and the antibiotic rifampicin (RIF) for 
reducing deep surgical site infections (Shiels et al., 2018; Tyas et al., 2018) or for the treatment of 
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tuberculosis. Many of these drugs are known to activate PXR and induce the expression of CYP3A 
before or after the onset of HS. For example, DEX, RIF,  statins and fibrates are typical agonists 
that preferentially activate the mouse and human PXR, respectively (Blumberg et al., 1998; 
Kliewer et al., 1998; Xie et al., 2000a). Besides regulating DMEs, activation of PXR has been 
shown to sensitize normal and cancerous tissues to oxidative cellular damage, but the mechanism 
is yet to be defined (Gong et al., 2006). Although the expression of PXR and DEMs has been 
reported to be dynamically regulated by HS (Edmonds et al., 2011), it is unclear whether and how 
PXR plays a role in the regulation of DMEs in the setting of HS and if so, whether activation of 
PXR is beneficial or detrimental to HS-induced hepatic injury.  
Another reason for our interests in PXR is that cytochrome P450 3A4 (CYP3A4) is the 
primary downstream gene regulated by PXR. CYP3A4 is a major member of cytochrome P450 
drug metabolism enzymes, who can oxidize small molecules such as steroids, fatty acids and drugs. 
Beyond mitochondria electron transport chain, P450-dependent microsomal electron transport 
system is believed to be another major endogenous source of ROS. It was reported as the most 
active P450 in catalyzing the formation of ROS, such as NADPH oxidation and the production of 
superoxide anion radicals (Hrycay and Bandiera, 2015), which are known to be important 
contributors to tissue damage after HS. CYP3A4 also presents high amount in human liver 
microsome. Therefore, we believe induction of CYP3A4 might be a critical factor in HS-induced 
liver injury through generating ROS. 
In this study, a fixed-pressure HS model (Figure 2) is used instead of fixed volume 
hemorrhage and uncontrolled hemorrhage, because the extent of hypotension, duration and the 
volume can be controlled. In this HS model, we did bilateral femoral artery cannulation and 
withdraw around 0.6 cc of blood from one side of artery and maintained the mean arterial pressure 
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at 25 mmHg for 2 h before resuscitation. Animals were sacrificed at 24 h after the initial of HS. 
Details can be found in 2.2 Experimental Procedures. 
 
Figure 2. The murine model of HS. 
Our results showed that activation of PXR sensitized both the wild-type and 
hPXR/CYP3A4 humanized mice to HS-induced hepatic injury in a CYP3A dependent manner. 
The sensitizing effect of PXR on HS-induced hepatic injury can be mitigated by inhibition of 
CYP3A, or treatment with an antioxidant, or a PXR antagonist.  
2.2 Experimental Procedures 
Animals and hemorrhagic shock 
The Pxr-/- (Xie et al., 2000a), VP-PXR transgenic (Xie et al., 2000a), and hPXR/CYP3A4 
humanized mice (Ma et al., 2008) were previously described. VP-PXR/Cyp3a-/- mice were 
generated by breeding the VP-PXR transgene into the Cyp3a-/- background (van Herwaarden et 
al., 2007). Eight-week old mice were used for hemorrhagic shock. Under anesthesia, catheters 
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were placed in both femoral arteries. To initiate HS, approximately 0.6 ml of blood were 
withdrawn using a syringe pump during which the blood pressure was maintained at approximately 
25 mmHg. After a 2-h pressure-controlled HS, mice were resuscitated using Lactated Ringers 
solution at a volume of 3x each animal’s shed blood volume given over a 15-min period using a 
syringe pump. In the sham control mice, the femoral arteries were exposed but not catheterized. 
Serum and tissue samples were collected 22 hours after resuscitation. The use of mice in this study 
complied with the relevant federal guidelines and institutional policies. 
 
Chemicals 
Ketoconazole (KET), dexamethasone (DEX) and pregnenolone 16α-carbonitrile (PCN) 
were purchased from Sigma-Aldrich (St. Louis, MO). KET was prepared for i.p. or oral 
administration by dissolution in ethanol and Tween 80 (1:1(v/v)) and then further dilution with 
saline. SPA70, the human PXR antagonist, is a kind gift from Dr. Taosheng Chen’s lab (St. Jude 
Children’s Research Hospital, Memphis). SPA70 was prepared for i.p. administration by 
dissolution in 30% PEG-400 dissolved in saline. 
 
Histology, immunohistochemistry, and immunofluorescence 
Five-micron thick tissue paraffin sections were stained with hematoxylin-eosin for general 
histology. Necrosis was estimated by dividing the necrotic area by the entire histological section 
using ImageJ software. Sections were scored from 0-4 for sinusoidal congestion, hydropic 
degeneration, necrosis, neutrophilic infiltration, and steatosis, and these parameters were used to 
calculate the Suzuki score as described (Suzuki et al., 1993) . For 4-hydroxynonenal (4-HNE) 
immunostaining, liver paraffin sections were incubated with the primary 4-HNE antibody 
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(Ab48506 from Abcam, Cambridge, MA) at 1:25 dilution overnight at 4 °C. The secondary 
antibody used was anti-mouse monoclonal at 1:500 dilution. The signal was visualized by 
peroxidase reaction using 3,3′-diaminobenzidine as the chromogen substrate. Hematoxylin was 
used as a nuclear counterstain. At least three mice were used for each treatment group or genotype, 
and for each sample at least four non-contiguous regions were photographed and analyzed. For 8-
hydroxyguanosine (8-OHdG) immunofluorescence, liver paraffin sections were incubated with 
primary 8-OHdG antibody (Ab48508 from Abcam, Cambridge, MA) at 1:200 dilution overnight 
at 4 °C. The secondary antibody used was a Cy3 (Cyanine 3) conjugated donkey anti-mouse 
monoclonal at 1:500 dilution. DAPI was used as a nuclear counterstain.  
 
Real-time PCR and Western Blot analysis 
Total RNA was extracted from tissues using the TRIzol reagent. Total RNA was treated 
with RNase-free DNase I and reverse transcribed into single stranded cDNA. Real-time PCR using 
the SYBR Green-based assay was performed with the ABI 7300 Real-Time PCR System. For 
Western blotting, 20 g of total protein for each sample were separated on 10% SDS-
polyacrylamide gel. The primary antibody was a monoclonal mouse antibody against 4-HNE 
(1:200) from Abcam (Ab48506). The primary antibody of Cyp2b10 (1:200) was a polyclonal 
rabbit antibody from Abcam (Ab9916), while the primary antibody of Cyp3a11/CYP3A4 (1:200) 
was a monoclonal mouse antibody obtained from Dr. Frank J Gonzalez’s lab (National Cancer 
Institue, NIH). 
 
Serum chemistry 
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Blood samples were collected by cardiac puncture. Serum aminotransferase (ALT) levels 
were measured using an assay kit from Stanbio (Boerne, TX). 
 
Analysis of microsomal metabolism of midazolam and oxycodone  
Microsomes were prepared from the mouse livers as described (Matsubara et al., 1974). 
Fifty mg liver tissue was homogenized with buffer A (0.1 M phosphate buffer, pH7.5; 0.25 M 
sucrose; 0.154 M KCl; 1mM protease inhibitor) and centrifuged at 100,000 g for 25 min at 4 °C. 
The pellets were washed once with buffer B (0.1 M phosphate buffer, 20% v/v glycerol) and 
resuspended in 200 µl buffer B. The metabolisms of midazolam and oxycodone were measured by 
incubating 0.5 mg/ml microsomes with 30 µM midazolam or 0.1 mg/ml microsome with 300 µM 
oxycodone in a tube containing 0.1 mM PBS (pH=7.4). The incubation was initiated by adding 1 
mM NADPH. After incubation for 10 min at 37 °C for midazolam or 120 min at 37 °C for 
oxycodone, 100 µl ice-cold methanol was added to stop the reaction. The samples were vortexed 
for 30 s, then centrifuged at 15000 rpm for 10 min. One hundred µl of supernatant was transferred 
to an autosampler vial for UPLC-MS analysis. The UPLC-MS analysis was performed as 
described (Fang et al., 2013; Tien et al., 2015). 
 
Statistical analysis 
Results are expressed as mean  SE. Differences between two individual groups were 
determined by Student’s t test. Differences between multiple groups were evaluated using one-
way analysis of variance followed by post-hoc multiple comparison according to the Student-
Newman-Keuls test. Statistical significance was accepted at p  0.05. 
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2.3 Experimental Results 
2.3.1 Genetic activation of PXR and Pxr ablation sensitize mice to and protect mice from 
HS-induced hepatic injury, respectively 
To investigate the role of PXR in hepatic injury following hemorrhagic shock and 
resuscitation (HS/R), we established a 2-h fixed pressure model of HS/R in which mice were 
sacrificed 22 h after the resuscitation (Kohut et al., 2011). As expected (Yu et al., 2008; Wetzel et 
al., 2014), HS led to hepatic injury, as evidenced by histological necrosis (Figure 3A), apoptosis 
of hepatocytes adjacent to the central vein (CV) (Figure 3B) that was consistent with the peri-CV 
expression of Cyp3a11 (Figure 3C), and increased serum level of alanine aminotransferase (ALT) 
(Figure 3D). In addition, qRT-PCR results showed that the expression of Pxr and several of its 
target genes, including Cyp3a11, Cyp2b10, Cyp2d22 and Cyp2c29, was down-regulated (Figure 
3E). The downregulation of Cyp3a11 was verified by Western blotting (Figure3). The down-
regulation of DMEs was also confirmed at the enzymatic level, because compared to the sham 
group, liver microsomes isolated from the HS group showed a decreased metabolism of sedative 
midazolam, a substrate of CYP3A (Figure 3G) and analgesic oxycodone, a substrate of both 
CYP3A and CYP2D (Figure 3H). Interestingly, we observed an intact expression of Pxr and a 
modest but significant increase in the expression of Cyp3a11 at the mRNA (Figure 3I) and protein 
(Figure 3J) levels in mice that were subject to a 2-h HS but without a resuscitation. These results 
suggested that the suppression of Pxr and Cyp3a in mice subject to HS/R may have been secondary 
to the liver injury; whereas the activation of PXR and induction of Cyp3a11 in the HS phase may 
have played a pathogenic role in the liver injury.  
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Figure 3. Hemorrhagic shock causes hepatic injury and affects the expression and activity of DMEs. 
(A) Liver histology of WT mice subject to sham surgery or HS/R was analyzed by H&E staining. The “N”s within 
the dotted circle indicate the necrotic areas. (B) Apoptosis was analyzed by TUNEL staining. CV, central vein. (C) 
The hepatic expression of Cyp3a11 was measured by immunostaining. (D) Mice are the same as in (A). Shown are 
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the serum levels of ALT. (E) The hepatic gene expression was measured by qRT-PCR. (F) The hepatic expression of 
Cyp3a11 was measured by Western blotting. (G) Schematic presentation of midazolam metabolism by CYP3A4 in 
human and Cyp3a11 in mice (left). The liver microsomal formation of 1’-OH midazolam was measured by UPLC-
MS (right). (H) Schematic presentation of oxycodone metabolism by CYP3A4 in human (Cyp3a11 in mice) and 
CYP2D6 in human (Cyp2d22 in mice) (left). The liver microsomal formations of noroxycodone and oxymorphone 
were measured by UPLC-MS (right). (I) The hepatic gene expression was measured by qRT-PCR in WT mice subject 
to sham surgery or HS without resuscitation. (J) Mice are the same as in (H). The hepatic protein expression of 
Cyp3a11 was measured by Western blotting. Results are presented as mean SE. n=4~5 for each group. *, p < 0.05; 
**, p < 0.01, compared to the sham groups. 
 
To determine the effect of PXR activation on HS-induced tissue injury, WT, Alb-VP-PXR 
transgenic, and Pxr-/- mice were subject to HS/R before being analyzed for their injury in the liver 
and lung, two tissues known to be sensitive to HS (Yu et al., 2008; Wen et al., 2014; Wetzel et al., 
2014). The Alb-VP-PXR transgenic mice express the constitutively activated PXR (VP-PXR) 
under the control of the liver-specific albumin gene promoter (Xie et al., 2000a). Wild type mice 
subject to HS/R showed hepatic injury, as shown by H&E staining (Figure 4A), quantification of 
necrotic area (Figure 4B), Suzuki score of the histology based on hydropic degeneration and 
steatosis (Suzuki et al., 1993) (Figure 4C), and the serum ALT level (Figure 4D). Compared to 
WT mice, VP-PXR transgenic mice showed heightened hepatic injury with a significant larger 
liver necrotic area and elevated serum ALT level when subjected to HS; while Pxr-/- mice showed 
attenuated hepatic injury (Figure 4A-4D). The expression of both Cyp3a11 and Cyp2b10 was 
induced in sham VP-PXR transgenic mice as expected, but the expression of both genes was 
suppressed upon HS/R (Figure 4E). Interestingly, the effect of PXR on HS-induced tissue injury 
was liver-specific, because there were no appreciable differences in HS-induced lung injury, 
including interstitial edema and infiltration of cells into the interstitial and alveolar spaces, among 
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the three genotypes (Figure 4F).  Compared to the liver, the lung had a very low expression of 
either Pxr or Cyp3a11 (data not shown). 
 
Figure 4. Genetic activation of PXR and Pxr ablation sensitize mice to and protect mice from HS-induced 
hepatic injury, respectively. 
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(A) WT, VP-PXR transgenic, and Pxr-/- mice subject to sham surgery or HS/R were analyzed for liver injury by H&E 
staining. The “N”s within the dotted circle indicate the necrotic areas. Bar is 100 μm. (B-E) Mice are the same as in 
(A). Shown are quantification of necrotic areas (B), Suzuki scores of the liver damage (C), and serum levels of ALT 
(D), and hepatic expression of Cyp3a11 and Cyp2b10 (E). (F) Mice in (A) were analyzed for lung injury by H&E 
staining (F). n=4~5 for each group. *, p < 0.05; **, p < 0.01, compared to the WT (B and C), or the comparisons are 
labeled (D and E). 
2.3.2 Pharmacological activation of PXR, but not CAR, sensitizes mice to HS-induced 
hepatic injury  
Since many clinical drugs, including those often prescribed to trauma patients, can activate 
PXR, we investigated whether a pharmacological activation of PXR can also sensitize mice to HS-
induced hepatic injury. WT and Pxr-/- mice were pre-treated with PCN (40 mg/kg per day, i.p.) or 
DEX (20 mg/kg per day, i.p.) for two days before receiving the HS/R surgery. PCN is a 
prototypical mouse Pxr agonist, whereas DEX is a mouse-preferred Pxr agonist and a widely-
prescribed glucocorticoid (Grinstein-Nadler and Bottoms, 1976; Zingarelli et al., 1994; Blumberg 
et al., 1998; Kliewer et al., 1998; Xie et al., 2000a). When PCN was used as outlined in Figure 5A, 
treatment of WT mice with PCN induced the expression of Cyp3a11 and Cyp2b10 at the mRNA 
(Figure 5B), protein (Figure 5C), and enzymatic (Figure 5D) levels in the sham group. PCN also 
induced the expression of Cyp3a11 in the HS/R group, which overrode the suppressive effect of 
HS/R on Cyp3a11 (Figure 5B-5D). As expected, PCN had little effect on the expression of 
Cyp3a11 in Pxr-/- mice regardless of HS/R (Figure 5B). Consistent with the results from the VP-
PXR transgenic mice, treatment with PCN also sensitized mice to HS-induced hepatic injury as 
shown by H&E staining, quantification of necrotic area, and Suzuki scores (Figure 5E), and the 
serum ALT level (Figure 5F). The sensitizing effect of PCN was abolished in Pxr-/- mice (Figure 
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5E-5H). A similar pattern of Pxr-dependent sensitization was observed in mice pre-treated with 
DEX (Figure 6). 
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Figure 5. Pharmacological activation of PXR sensitizes mice to HS-induced hepatic injury. 
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 (A) Schematic representation of the PCN pre-treatment model. WT and Pxr-/- mice were intraperitoneally injected 
with PCN (40 mg/kg per day) for two days before receiving the sham surgery or HS/R. (B and C) The hepatic mRNA 
(B) and protein (C) expression of Cyp3a11 and Cyp2b10 were measured by qRT-PCR and Western blotting, 
respectively. (D) The liver microsomal productions of 1’-OH midazolam (left) and noroxycodone (right) were 
measured by UPLC-MS analysis. (E) Liver histology was analyzed by H&E staining. Bar is 100 μm. Shown below 
are quantification of necrotic areas and Suzuki scores. (F) Serum levels of ALT. n=4~5 for each group. *, p < 0.05; 
**, p < 0.01, the comparisons are labeled (B, D and F), or compared to the WT+VEH group (E). 
 
Figure 6. Treatment with DEX sensitizes mice to HS-induced hepatic injury in a PXR-dependent manner. 
 (A) Schematic representation of the DEX pre-treatment model. WT and Pxr-/- mice were intraperitoneally injected 
with DEX (20 mg/kg per day) for two days before receiving the sham surgery or HS/R. (B) The hepatic mRNA 
expression of Cyp3a11 was measured by qRT-PCR. (C) Liver histology was analyzed by H&E staining. Bar is 100 
μm. (D-F) Mice are the same as in (C). Shown are quantification of necrotic areas (D), Suzuki scores (E), and serum 
levels of ALT (F) in mice subject to HS/R. Results are presented as mean SE. n=4~5 for each group. *, p < 0.05; **, 
p < 0.01, the comparisons are labeled (B and F), or compared to WT+VEH (D and E).  
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The constitutive androstane receptor (CAR) is a sister xenobiotic receptor of PXR. To 
determine whether activation of CAR can also sensitize mice to HS-induced hepatic injury, WT 
mice were pre-treated with TCPOBOP (0.25 mg/kg, i.p.), a potent CAR agonist, for 3 days before 
the HS/R surgery (Figure 7A). As expected, TCPOBOP induced the expression of Cyp2b10, a 
primary target gene of CAR (Figure 7B). However, TCPOBOP had little effect on HS-induced 
hepatic injury, as shown by histology (Figure 7C-7E). These results suggested that the sensitizing 
effect was PXR specific. 
 
Figure 7. Treatment with the CAR agonist TCPOBOP fails to sensitize mice to HS-induced hepatic injury. 
 (A) Schematic representation of the TCPOBOP pre-treatment model. WT mice were intraperitoneally injected with 
TCPOBOP (0.25 mg/kg per day) for three days before receiving the sham surgery or HS/R. (B) The hepatic mRNA 
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expression of Cyp2b10 was measured by qRT-PCR. (C) Liver histology was analyzed by H&E staining. Bar is 100 
μm. (D and E) Mice are the same as in (C). Shown are quantification of necrotic areas (D) and Suzuki scores (E) in 
mice subject to HS/R. Results are presented as mean SE. n=4~5 for each group. *, p < 0.05; **, p < 0.01, the 
comparisons are labeled.  
2.3.3 Induction of CYP3A is required for the sensitizing effect of PXR activation on HS-
induced hepatic injury 
Since CYP3A is the primary target gene of PXR and a major source of ROS production 
that contributes to liver damage (Puntarulo and Cederbaum, 1998; Jaeschke, 2011; Tsai et al., 
2015; Logsdon et al., 2016), we went on to use CYP3A loss-of-function models to determine 
whether the expression and regulation of CYP3A were required for the heightened HS-induced 
hepatic injury in VP-PXR transgenic mice. The inhibition of CYP3A was achieved 
pharmacologically by treating mice with ketoconazole (KET) (Anderson and Blaschke, 1986), or 
genetically by using the Cyp3a knockout (Cyp3a-/-) mice that bear the deletion of a cluster of 
mouse Cyp3a genes (van Herwaarden et al., 2007; Ma et al., 2008). In the pharmacological model, 
WT and VP-PXR transgenic mice were pre-treated with vehicle or KET (95 mg/kg per day, p.o.) 
for three days before receiving the HS/R surgery (Figure 8A). KET attenuated HS-induced hepatic 
injury in WT mice, and this attenuating effect was more dramatic in VP-PXR transgenic mice, as 
shown by histology (Figure 8B and 8C) and serum ALT level (Figure 8D).  
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Figure 8. Induction of CYP3A is required for the sensitizing effect of PXR activation on HS-induced hepatic 
injury. 
(A) Schematic representation of the ketoconazole (KET) pre-treatment model. WT and VP-PXR transgenic mice were 
treated with KET (20 mg/kg per day) for two days before receiving the sham surgery or HS/R. (B and C) Liver 
histology was analyzed by H&E staining (B, Bar is 100 μm), and quantification of necrotic areas and Suzuki scores 
(C). (D) Serum levels of ALT. (E) VP-PXR and VP-PXR/Cyp3a-/- mice subject to the sham surgery or HS/R were 
analyzed for liver histology by H&E staining. Shown on the right are quantification of necrotic areas and Suzuki 
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scores. (F) Serum levels of ALT. n=4~5 for each group. *, p < 0.05; **, p < 0.01, the comparisons are labeled (C, D, 
and F), or compared to the VP-PXR group (E). 
 
Since trauma patients often receive treatment after their admissions to ICU, we evaluated 
the effect of post-HS treatment of KET on PCN-induced and HS/R responsive hepatic injury. Two 
time points of post-HS KET treatment were chosen: 2 h after the initiation of HS and right before 
resuscitation when Cyp3a11 was induced (Figure 3I and 3J), and 12 h after the initiation of HS 
when the suppression of Cyp3a11 became obvious (Figure 9A). The designs of the experiment are 
outlined in Figure 9B. Treatment with KET at the 2-h time point, but not the 12-h time point, was 
effective to attenuate HS-induced hepatic injury as shown by histology (Figure 9C-9E) and the 
serum ALT level (Figure 9F). The loss of protection at the 12-h time point was likely due to the 
suppression of Cyp3a11. Nevertheless, these results suggested that the effect of post-HS treatment 
of KET was time-sensitive.  
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Figure 9. Post-hemorrhagic shock treatment of CYP3A inhibitor KET attenuates HS-induced hepatic injury. 
(A) The hepatic mRNA expression of Cyp3a11 at indicated time points after HS was measured by qRT-PCR. (B) 
Schematic representation of the KET post-HS treatment model. WT mice were intraperitoneally injected with PCN 
(40 mg/kg) or VEH for two days before receiving the sham surgery or HS/R. KET (95 mg/kg) or VEH was given 
either 2-h after the initiation of HS (at 72 h), or 12-h after the initiation of HS (at 84 h). (C) Liver histology was 
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analyzed by H&E staining. Bar is 100 μm. (D-F) Mice are the same as in (C). Shown are quantification of necrotic 
areas (D), Suzuki scores (E), and serum ALT levels (F) in mice subject to HS/R. Results are presented as mean SE. 
n=3 for each group. *, p < 0.05; **, p < 0.01, compared to VEH (D and E), or the comparisons are labeled (F). 
 
In the genetic model, we generated the VP-PXR/Cyp3a-/- mice by breeding the VP-PXR 
transgene into the Cyp3a-/- background. The VP-PXR and Cyp3a-/- alleles were verified by PCR 
genotyping (Figure 10A) and the loss of Cyp3a expression was confirmed by qRT-PCR (Figure 
10B). In the same VP-PXR/Cyp3a-/- mice, the expression of Cyp2b10 was induced (Figure 10B), 
consistent with the notion that Cyp2b10 is a PXR target gene. Compared to their VP-PXR 
counterparts, VP-PXR/Cyp3a-/- mice showed attenuated liver injury upon HS/R (Figure 8E and 
8F). These results suggested that the sensitizing effect of the VP-PXR transgene was Cyp3a11 
dependent, but independent of Cyp2b10. Ablation of Cyp3a also attenuated the sensitizing effect 
of PCN (Figure 10C-10F).  
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Figure 10. Ablation of Cyp3a abolishes the sensitizing effect of PCN. 
(A) PCR genotying to validate the creation of VP-PXR/Cyp3a-/- mice. (B) The hepatic mRNA expression of Cyp3a11 
and Cyp2b10 was measured by qRT-PCR. (C) Liver histology was analyzed by H&E staining in PCN-treated WT and 
Cyp3a-/- mice subject to sham surgery or HS/R. Bar is 100 μm. (D-F) Mice are the same as in (C). Shown are 
quantification of necrotic areas (D), Suzuki scores (E), and serum levels of ALT (F) in mice subject to HS/R. Results 
are presented as mean SE. n=3 for each group. *, p < 0.05; **, p < 0.01, compared to WT. 
2.3.4 Pharmacological activation of hPXR sensitizes the hPXR/hCYP3A4 humanized mice 
to HS-induced hepatic injury in a CYP3A-dependent manner 
The drug induction of DMEs is known to have species specificity, and original hPXR 
humanized mice showed that the species origin of the PXR receptor is the determining factor for 
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the species specificity (Xie et al., 2000a). The second-generation of humanized mice were 
subsequently created by humanizing both hPXR and human CYP3A4. The humanization of 
CYP3A4 was achieved by introducing the CYP3A4 transgene into the Cyp3a-/- background (Ma 
et al., 2008). We used the hPXR/hCYP3A4 humanized mice and the control hPXR/Cyp3a-/- mice 
to determine whether activation of hPXR by RIF, an antibiotic and potent hPXR-specific agonist, 
can sensitize mice to HS-induced hepatic injury and whether this sensitization is CYP3A 
dependent. The humanized mice were pre-treated with RIF (10 mg/kg per day, i.p.) for 4 days 
before the HS/R surgery (Figure 11A). Treatment with RIF was efficient in inducing CYP3A4 as 
expected (Figure 11B), and the massive induction of CYP3A4 caused the loss of zonal expression 
of CYP3A4 (Figure 11C). The humanized mice showed a basal sensitivity to HS-induced hepatic 
injury similar to WT mice, and the liver injury was exacerbated by the treatment of RIF, as shown 
by histology (Figure 11D) and serum ALT level (Figure 11E). The sensitizing effect of RIF was 
attenuated in hPXR/Cyp3a-/- mice, suggesting that the sensitizing effect was CYP3A dependent 
(Figure 11D and 11E). 
 28 
 
Figure 11. Pharmacological activation of hPXR sensitizes the hPXR/hCYP3A4 humanized mice to HS-
induced hepatic injury in a CYP3A-dependent manner. 
 (A) Schematic representation of the rifampicin (RIF) pre-treatment model. WT, hPXR/CYP3A4 and hPXR/Cyp3a-/- 
mice were treated with RIF (10 mg/kg per day) for four days before receiving the sham surgery or HS/R. (B) The 
hepatic mRNA expression of human CYP3A4 and mouse Cyp3a11 was measured by qRT-PCR. (C) The hepatic 
expression of CYP3A4 was measured by immunostaining. CV, central vein; P, portal vein. (D) Liver histology was 
analyzed by H&E staining. Bar is 100 μm. Shown below are quantification of necrotic areas and Suzuki scores. (E) 
Serum levels of ALT. n=4~5 for each group. *, p < 0.05; **, p < 0.01, the comparisons are labeled. 
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2.3.5 The sensitizing effect of PXR on HS-induced hepatic injury is accompanied by 
increased oxidative stress 
CYP3A-mediated oxidation is an important source of ROSs (Puntarulo and Cederbaum, 
1998; Jaeschke, 2011; Tsai et al., 2015; Logsdon et al., 2016). Activation of PXR has been reported 
to sensitize mice to oxidative stress, such as those triggered by the oxidative toxicant paraquat 
(Gong et al., 2006). Having shown that induction of CYP3A is required for the sensitizing effect 
of PXR on HS-induced hepatic injury, we went on to determine whether the sensitizing effect of 
PXR was associated with an increased oxidative stress. Upon HS/R and compared to WT mice, 
the immunostaining of 4-hydroxynonenal (4-HNE), the α,β-unsaturated hydroxyalkenal produced 
by lipid peroxidation and an oxidative stress biomarker (Tjalkens et al., 1999), was increased in 
VP-PXR transgenic mice and PCN-treated WT mice, but decreased in Pxr-/- mice (Figure 12A). 
The respective increased and decreased oxidative stress in HS/R-treated VP-PXR and Pxr-/- mice 
were further verified by Western blot analysis of 4-HNE (Figure 12B) and immunofluorescence 
of 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker for free radicals induced by oxidative 
DNA lesions (Valavanidis et al., 2009) (Figure 12C). Consistent with the notion that Cyp3a 
enzymes reside in the endoplasmic reticulum, the hepatic expression of activating transcription 
factor 3 (Atf3) (Figure 12D) and C/EBP homologous protein (Chop) (Figure 12E), two ER stress 
sensors (Edagawa et al., 2014; Dai et al., 2017), was increased in VP-PXR mice upon HS/R. The 
increased HS-responsive oxidative stress in VP-PXR transgenic mice and RIF-treated 
hPXR/hCYP3A4 humanized mice was Cyp3a dependent, because these effects were abolished in 
VP-PXR/Cyp3a-/- mice and hPXR/Cyp3a-/- mice (Figure 12F), respectively, as shown by 
immunofluorescence of 8-OHdG.  
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Figure 12. The sensitizing effect of PXR on HS-induced hepatic injury is accompanied by increased oxidative 
stress. 
(A) Immunostaining of 4-HNE in liver tissues from WT, VP-PXR, WT+PCN, and Pxr-/- mice subject to the sham 
surgery or HS/R. Arrowheads indicate positive staining. (B) The level of 4-HNE was measured by Western blotting. 
(C) Immunofluorescent staining of 8-OHdG in liver tissue from WT, VP-PXR and Pxr-/- mice. (D) The hepatic 
expression of Atf3 and Chop was measured by qRT-PCR. (E and F) Immunofluorescent staining for 8-OHdG in liver 
tissues from WT, VP-PXR and VP-PXR/Cyp3a-/- mice that were subject to HS/R (E), or VEH- or RIF-treated 
hPXR/CYP3A4 and hPXR/Cyp3a-/- mice that were subject to HS/R (F). Bars are 100 μm. n=4~5 for each group. *, p 
< 0.05; **, p < 0.01, the comparisons are labeled. 
 
Treatment with the antioxidant NACA attenuates the sensitizing effect of PXR on HS-
induced hepatic injury  
To determine whether treatment with an antioxidant can attenuate the sensitizing effect of 
the VP-PXR transgene, VP-PXR transgenic mice were pre-treated with the antioxidant N-
acetylcystein amide (NACA, 200 mg/kg, i.p.) (Guo et al., 2015) one hour before the initiation of 
HS/R. Treatment with NACA attenuated HS-induced hepatic injury, as shown by histology (Figure 
13A-13C) and serum ALT level (Figure 13D). The HS-induced increase of 4-HNE 
immunostaining in the transgenic mice was also attenuated upon the NACA treatment (Figure 
13E). Treatment of WT mice with NACA also attenuated the sensitizing effect of PCN and DEX 
on HS-induced hepatic injury (Figure 14). Co-treatment of the VP-PXR transgenic mice with KET 
and NACA fully abolished the HS-induced hepatic injury (Figure 15). 
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Figure 13. Treatment with the antioxidant NACA attenuates the sensitizing effect of PXR on HS-induced 
hepatic injury. 
(A) Liver histology was analyzed by H&E staining in VEH- or NACA-treated VP-PXR mice that were subject to the 
sham surgery or HS/R. Bar is 100 μm. (B to D) Mice are the same as in (A). Shown are quantification of necrotic 
areas (B), Suzuki scores (C), and serum levels of ALT (D) in mice subject to HS/R. (E) Mice are the same as in (A). 
The level of 4-HNE was measured by immunostaining with the positive staining indicated by arrowheads. Bar is 100 
μm. n=4~5 for each group. *, p < 0.05; **, p < 0.01, compared to the VEH group (B and C), or the comparisons are 
labeled (D). 
 33 
 
 
Figure 14. Treatment with the antioxidant NACA attenuates the sensitizing effect of PCN and DEX on HS-
induced hepatic injury. 
(A-B) WT mice were treated with PCN or DEX, in the absence or presence of NACA, before receiving the sham 
surgery or HS/R. (A) Liver histology was analyzed by H&E staining. Bar is 100 μm. (B) Serum levels of ALT. Results 
are presented as mean SE. n=4 for each group. *, p < 0.05; **, p < 0.01, the comparisons are labeled. 
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Figure 15. Co-treatment of the VP-PXR transgenic mice with CYP3A inhibitor KET and antioxidant NACA 
abolishes HS-induced hepatic injury. 
(A) Schematic representation of the KET and NACA co-treatment model. VP-PXR transgenic mice were pre-treated 
with KET (95 mg/kg per day) for three days and intraperitoneally injected with NACA one hour before the sham 
surgery or HS/R. (B) Liver histology was analyzed by H&E staining. Bar is 100 μm. (C) Serum levels of ALT. Results 
are presented as mean SE. n=3 for each group. *, p < 0.05; **, p < 0.01, the comparisons are labeled. 
 
To evaluate the therapeutic potential of NACA, we conducted the post-HS treatment of 
NACA 2 h after HS but before the initiation of resuscitation (Figure 16A). Post-HS treatment of 
NACA also attenuated PCN-induced and HS-responsive hepatic injury, as shown by histology 
(Figure 16B-16D) and serum ALT level (Figure 16E). 
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Figure 16. Post-hemorrhagic shock treatment of NACA attenuates HS-induced hepatic injury. 
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(A) Schematic representation of the NACA post-HS treatment model. WT mice were intraperitoneally injected with 
PCN (40 mg/kg) or VEH for two days before receiving the sham surgery or HS/R. NACA (200 mg/kg) or saline was 
given 2 hours after the initiation of HS and before the resuscitation. (B) Liver histology was analyzed by H&E staining. 
Bar is 100 μm. (C-E) Mice are the same as in (B). Shown are quantification of necrotic areas (C), Suzuki scores (D), 
and serum levels of ALT (E) in mice subject to HS/R. Results are presented as mean SE. n=3 for each group. *, p < 
0.05; **, p < 0.01, the comparisons are labeled.  
2.3.6 Post-hemorrhagic shock activation of PXR sensitizes mice to HS-induced hepatic 
injury 
Since many trauma patients receive PXR-activating drugs upon their admissions to ICU, 
we investigated whether post-HS pharmacological activation of PXR can also sensitize mice to 
HS-induced hepatic injury. In this experiment, WT mice were subject to the HS surgery first, and 
right before the resuscitation, mice received a single intraperitoneal injection of PCN (40 mg/kg) 
or DEX (20 mg/kg) (Figure 17A). The activation of PXR and induction of Cyp3a11 were verified 
by qRT-PCR (Figure 17B). Post-HS treatment with PCN or DEX also exacerbated HS-induced 
hepatic injury as shown by histology (Figure 17C) and serum ALT level (Figure 17D). Post-HS 
treatment with PCN or DEX also increased HS-responsive oxidative stress as shown by 
immunofluorescence of 8-OHdG (Figure 17E). When the post-HS treatment of PCN was repeated 
in Cyp3a-/- mice, we found that PCN can no longer sensitize these mice to HS-induced hepatic 
injury (Figure 18), suggesting that the sensitizing effect of post-HS activation of PXR was also 
Cyp3a dependent.  
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Figure 17. Post-hemorrhagic shock activation of PXR sensitizes mice to HS-induced hepatic injury. 
(A) Schematic representation of the model of post-HS treatment of PCN or DEX. WT mice were subject to a 2-h HS 
and intraperitoneally injected with PCN (40 mg/kg) or DEX (20 mg/kg) before the resuscitation. and the mice were 
sacrificed 22 h after. (B) The hepatic mRNA expression of Cyp3a11 was measured by qRT-PCR. (C) Liver histology 
was analyzed by H&E staining. Shown on the right are quantification of necrotic areas and Suzuki scores. (D) Serum 
levels of ALT. (E) Immunofluorescent staining for 8-OHdG. Bar is 100 μm. n=4~5 for each group. *, p < 0.05; **, p 
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< 0.01, the comparisons are labeled (B and D), or compared to the VEH group (C). 
 
Figure 18. Ablation of Cyp3a abolishes the sensitizing effect of post-hemorrhagic shock treatment of PCN. 
(A) Schematic representation of the PCN post-HS treatment model. Cyp3a-/- mice were intraperitoneally injected with 
PCN (40 mg/kg) 2 hours after the initiation of HS and right before resuscitation. (B) Liver histology was analyzed by 
H&E staining. Bar is 100 μm. (C) Serum levels of ALT. Results are presented as mean SE. n=3 for each group.  
2.3.7 Treatment with the hPXR antagonist SPA70 protects the hPXR/hCYP3A4 humanized 
mice from HS-induced hepatic injury in a time-sensitive manner 
To determine whether a pharmacological inhibition of PXR can protect mice from HS/R-
induced hepatic injury, humanized mice treated with RIF (10 mg/kg), in the absence or presence 
of a recently reported human-specific PXR antagonist SPA70 (150 mg/kg) (Lin et al., 2017), for 
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3 days were subject to HS/R (Figure 19A). Treatment with SPA70 efficiently blocked RIF-
responsive induction of CYP3A4 as reported (Lin et al., 2017) (Figure 19B). SPA70 also 
attenuated HS/R-responsive and RIF-exacerbated hepatic injury as shown by histology (Figure 
19C) and the serum ALT level (Figure 19D). In addition, SPA70 attenuated HS/R-induced 
oxidative stress, as shown by immunostaining of 4-HNE (Figure 19E), immunofluorescence of 8-
OHdG (Figure 19F), and measurement of the expression of Atf3 and Chop (Figure 19G).  
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Figure 19. Treatment with the hPXR antagonist SPA70 protects the hPXR/hCYP3A4 humanized mice from 
HS-induced hepatic injury. 
(A) Schematic representation of the SPA70 pre-treatment model. Mice were intraperitoneally injected with VEH, RIF 
(10 mg/kg) and SPA70 (150 mg/kg) individually or in combination for 3 days before receiving the sham surgery or 
HS/R. (B) The hepatic mRNA expression of CYP3A4 was measured by qRT-PCR. (C) Liver histology was analyzed 
by H&E staining. Shown on the right are quantification of necrotic areas and Suzuki scores. (D) Serum levels of ALT. 
(E and F) The hepatic levels of 4-HNE (arrowheads indicated the positive staining) (E) and 8-OHdG (F) were 
measured by immunostaining and immunofluorescence, respectively. (G) The hepatic mRNA expression of Atf3 and 
Chop was measured by qRT-PCR. Bars are 100 μm. n=4~5 for each group. *, p < 0.05; **, p < 0.01, the comparisons 
are labeled. 
 
The protective effect of SPA70 was time-sensitive, because when given at 2-h or 12-h after 
the initiation of HS (Figure 20A), SPA70 failed to protect humanized mice from RIF-induced and 
HS/R-responsive hepatic injury (Figure 20B-20E). The lack of post-HS effect of SPA70 was likely 
due to the insufficient time to inhibit RIF-responsive expression of CYP3A4 (Figure 20F). In the 
same set of experiments, treatment with KET at the 2-h time point, but not the 12-h time point, 
was effective to attenuate HS-induced hepatic injury (Figure 20B-20E). 
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Figure 20. Effects of post-hemorrhagic shock treatment of SPA70 and KET on HS-induced hepatic injury in 
humanized mice. 
(A) Schematic representation of the SPA70/KET post-HS treatment model. Mice were intraperitoneally injected with 
RIF (10 mg/kg) for three days before receiving the sham surgery or HS/R. SPA70 (150 mg/kg), KET(95 mg/kg), or 
VEH was administrated either 2-h after the initiation of HS (at 72 h), or 12-h after the initiation of HS (at 84 h). (B) 
Liver histology was analyzed by H&E staining. Bar is 100 μm. (C-E) Mice are the same as in (B). Shown are 
quantification of necrotic areas (C), Suzuki scores (D), and serum levels of ALT (E) in mice subject to HS/R. (F) The 
hepatic mRNA expression of CYP3A4 in RIF-treated sham groups. Results are presented as mean SE. n=3 for each 
group. *, p < 0.05; **, p < 0.01, compared to the VEH group (C and D), or the comparisons are labeled (E and F). 
2.4 Discussion and conclusion 
HS remains a major health concern due to the secondary tissue and organ injuries. A better 
understanding of the mechanisms by which HS induces tissue injury will help to develop effective 
therapeutic strategies to reduce the mortality of organ injury, including injury to the liver. Our 
previous microarray analysis suggested a major suppression in the expression of PXR and its target 
DMEs (Edmonds et al., 2011), based on which we initially speculated that the suppression of PXR 
might have contributed to HS-induced hepatic injury. To our surprise, we found that the activation 
of PXR exacerbated hepatic injury following HS, while Pxr ablation or pharmacological inhibition 
of PXR in humanized mice by SPA70 protected mice from HS-induced hepatic injury. The 
pathological role of PXR activation in HS-induced hepatic injury was consistent with our 
observation that there was an intact expression of Pxr and elevated expression of Cyp3a11 in mice 
that received the 2-h HS but without a resuscitation. Our results suggest that HS has a dynamic 
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effect on the expression of Pxr and DMEs, and the HS-responsive suppression of PXR may 
represent a protective response and/or secondary response to HS-induced hepatic injury.   
Our study is of medical significance. This is because seriously injured trauma patients are 
uniformly prescribed with multiple drugs, many of which are PXR activators and DME inducers 
in the liver. The unavoidable use of PXR-activating drugs prior to HS or during the clinical 
management of trauma may restore drug metabolism, but has the potential to exacerbate HS-
induced hepatic injury. We showed both pre-HS and post-HS activation of PXR sensitized mice 
to HS-induced hepatic injury. The pre-treatment with PXR agonists simulates HS patients who 
happen to take PXR-activating drugs prior to their injury, whereas treatment during resuscitation 
mimics HS patients who receive PXR-activating medications during their ER visit or ICU stay. 
The human relevance of this study was also illustrated by our use of the hPXR/hCYP3A4 
humanized mice, in which treatment with RIF, an antibiotic to reduce deep surgical site infections 
(Shiels et al., 2018; Tyas et al., 2018) or to treat tuberculosis, sensitized these mice to HS-induced 
hepatic injury.  
The mechanistic insight revealed from this study may provide translational opportunities. 
We have presented both pharmacological and genetic evidence that the induction of CYP3A is 
required for the sensitizing effect of PXR on HS-induced hepatic injury. The initial evidence was 
that treatment with the CYP3A inhibitor KET attenuated the VP-PXR transgenic mice from HS-
induced hepatic injury. In addition to inhibiting Cyp3a enzymes, KET and its derivatives can also 
function as PXR antagonists (Wang et al., 2007). Therefore, we cannot exclude the possibility that 
inhibition of both Cyp3a and PXR may have contributed to the protective effect of KET. To more 
conclusively define the role of CYP3A, we showed that ablation of the Cyp3a genes abolished the 
sensitizing phenotype in VP-PXR transgenic mice, PCN- or DEX-treated WT mice, or RIF-treated 
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humanized mice. Pharmacoenhancing by CYP3A inhibition is not uncommon in the clinic. It is 
interesting to know whether pharmacoenhancers, such as Ritonavir used in the HIV antiretroviral 
therapy (Saag et al., 2018), can be used to attenuate the sensitizing effect of PXR activation. The 
use of antioxidant NACA to relieve the sensitizing effect of PXR was also exciting, because the 
oral formulation of N-acetylcysteine (NAC) is a drug approved for treating APAP overdose whose 
mechanism of hepatotoxicity also involves oxidative stress (Yan et al., 2018). The use of hPXR 
antagonist SPA70 to attenuate RIF-induced sensitization in humanized mice provided a proof of 
concept evidence that a direct use of PXR antagonists may also be used to manage PXR-mediated 
sensitization of HS-responsive liver injury. Last but not least, it is encouraging that post-HS 
administration of NACA and KET remained effective in alleviating PXR-induced and HS/R-
responsive hepatic injury.  
In summary of Chapter II, we have uncovered a previously unrecognized role of PXR in 
HS-induced hepatic injury (Figure 21). Cautions need to be applied when PXR-activating drugs 
are used in trauma patients, or when patients were on PXR-activating drugs prior to their traumatic 
injuries. Our results also suggest that co-administration of anti-oxidative agents, CYP3A 
inhibitors, and/or PXR antagonists can be used to mitigate the side effect of liver injury associated 
with the unavoidable use of PXR-activating drugs in trauma patients.  
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Figure 21. Summary of Chapter II. 
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3.0 Estrogen sulfotransferase and hemorrhagic shock-induced acute lung injury 
3.1 Estrogen sulfotransferase in liver disease 
3.1.1 The superfamily of sulfotransferases 
Sulfate conjugation (sulfation or sulfonation) is a major conjugating pathway responsible 
for the deactivation, detoxification and excretion of xenobiotics and endogenous molecules 
(Falany, 1991). Sulfoconjugation was first recognized as an important metabolic pathway by 
Baumann in 1876 (Baumann, 1876). At the chemical level, the cytosolic sulfotransferases (SULTs) 
catalyze the transfer of a negatively charged sulfonate group (SO3-) from the universal sulfate 
donor 3′- phosphoadenosine-5′-phosphosulfate (PAPS) onto a nucleophilic group of their 
substrates to generate hydrophilic products, which often promote the urinary excretion of the 
substrates. The high-energy sulfate donor PAPS can be generated by PAPS synthases, including 
PAPSS1 and PAPSS2, as well as by ATP sulfurylase and two forms of adenosine 5ʹ-
phosphosulfate kinase (APS kinases) (Mueller et al., 2018).  
SULTs are widely expressed in the liver, as well as metabolically active or hormonally 
responsive extrahepatic tissues (Dooley et al., 2000; Gamage et al., 2006). This large family of 
enzymes are responsible for sulfating a variety of endogenous and exogenous molecules, including 
pharmaceuticals, procarcinogens, hormones, neurotransmitters, as well as intermediates of 
endogenous metabolism (Dooley et al., 2000; Glatt et al., 2001; Negishi et al., 2001; Jancova et 
al., 2010). Sulfation often results in the inactivation of the substrates or reduced potency of ligands 
(Strott, 2002; Bjerregaard-Olesen et al., 2015) but with some exceptions. Their abundance in the 
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liver and wide range of substrates suggest SULTs may act as important mediators for the 
development of liver diseases, such as hepatocellular carcinoma (Xie et al., 2017; Zou et al., 2017), 
liver fibrosis (Hardwick et al., 2013; Krattinger et al., 2016; Yetti et al., 2018), and drug-induced 
liver injury (Fang et al., 2016). Therefore, in this review we focus on the roles of the human and 
rodent SULTs in liver diseases. 
The SULTs superfamily contains 62 human SULT genes and 46 murine homologues as of 
2016 (Mueller et al., 2015; Herrero et al., 2016). Among SULTs, the aryl-sulfotransferase (SULT1) 
and the hydroxysteroid sulfotransferase (SULT2) families are two principal sub-families of SULTs 
that are the major contributors to the sulfonation of many xenobiotics including pharmaceuticals 
and procarcinogens, and endobiotics including steroids, thyroid, and neurotransmitters (Kauffman, 
2004; Reinen and Vermeulen, 2015).  
SULT1 family comprises five isoforms: phenol-sulfotransferases (SULT1A1/2) 
(Raftogianis et al., 1999), catecholamine phenol sulfotransferase (SULT1A3/4) that is only present 
in humans (Zou et al., 2017), thyroid hormone sulfotransferase (SULT1B1) (Saeki et al., 1998), 
iodothyronine sulfotransferase (SULT1C2,1C4) (Dubaisi et al., 2019), and estrogen 
sulfotransferase (EST/SULT1E1) (Zhang et al., 1998; Guo et al., 2015). SULT2 family has two 
isoforms: SULT2A1 that sulfonates 3-hydroxysteroids (Mueller et al., 2018) and bile acids (Huang 
et al., 2010), and SULT2B1b that has a greater selectivity for 3-hydroxysteroids, such as 
cholesterol (Bi et al., 2018), but not for bile acids. 
In addition to the SULT1 and SULT2 families of enzymes, the human genome contains 
two more sulfotransferase gene families, SULT4 and SULT6, encoding enzymes including 
SULT4A1 that is a brain-specific sulfotransferase associated with antipsychotic treatment 
response (Wang et al., 2014) and SULT6B1 whose physiological function is largely unknown. 
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3.1.2 Estrogen Sulfotransferase in liver diseases 
3.1.2.1 EST in liver cancer 
Estrogen sulfotransferase (SULT1E1, also known as EST), widely expressed in human 
tissues such as the liver, lung, adipose tissue, and kidney (Barbosa et al., 2019), is best known for 
its function in the sulfoconjugation and deactivation of estrogens. This is because sulfonated 
estrogens fail to bind to the estrogen receptor and thus lose their hormonal activities (Song, 2001). 
As such, SULT1E1 has long been implicated in female sex hormone related cancer, such as breast, 
endometrial, and ovarian cancers (Pasqualini, 2009; Mungenast et al., 2017; Sinreih et al., 2017; 
Xu et al., 2018). Interestingly, SULT1E1 is also reported to be associated with the occurrence of 
HCC in rats. In a study on inflammatory liver disease, upregulation of Sult1e1 in diethynitrosamine 
(DEN)-treated mouse livers was observed compared to the vehicle-treated livers using real time 
RT-PCR (Lee et al., 2017). However, in the DEN-induced rat model of hepatoma, the expression 
of SULT1E1 was decreased with the onset of hepatomas (Albrethsen et al., 2011). The causal 
relationship remains to be defined, because the expression of SULT1E1 was increased in 
regenerating liver (Albrethsen et al., 2011). Moreover, the species difference and the human 
relevance of SULT1E1 in liver cancer need to be clarified.  
3.1.2.2 EST in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 
(NASH)     
Previous study in our lab found that loss of Sult1e1/Est in female mice improved metabolic 
function with improved insulin sensitivity and reduced hepatic steatosis in ob/ob mice lacking 
Sult1e1 (also known as the obe mice), compared to the ob/ob (Gao et al., 2012). In an independent 
study, Sult1e1 was suggested to play a role in sensitizing male mouse to NAFLD/NASH induced 
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by a 20-wk feeding of a Western diet high in cholesterol and saturated fat diet (HCFD) (Matsushita 
et al., 2017). The authors found that NASH was attenuated in IkbkbΔmye mice with myeloid IKKβ 
deficiency in both genders but aggravated in male but not female IkbkbΔhep mice with hepatocyte 
IKKβ deficiency. Microarray analysis on liver tissues from male and female WT and IkbkbΔhep 
mice fed HCFD showed a significant upregulation of Sult1e1 gene in IkbkbΔhep mice compared 
to WT mice. Among the four groups, the male IkbkbΔhep mice expressed the highest level of 
Sult1e1 gene which was associated with decreased plasma estradiol levels. The authors’ 
mechanism study indicated that the enrichment of LXRα to LXRE on the Sult1e1 gene promoter 
of male IkbkbΔhep mice might be responsible for their heightened sensitivity to NASH. These 
results suggest hepatocyte IKKβ is protective in males due at least in part to its ability to repress 
LXR responsive induction of Sult1e1 (Matsushita et al., 2017).  
3.1.2.3 EST in liver injury induced by sepsis and ischemia /reperfusion 
SULT1E1 is relatively thoroughly studied in inflammation-based conditions. Sepsis, 
resulting from the host's deleterious systemic inflammatory response to microbial infections, is a 
major cause of mortality in the intensive care unit. Although sepsis and its associated inflammation 
are known to decrease the expression and activity of many drug metabolizing enzymes, we 
observed a major induction of Sult1e1 and compromised estrogen activity in the liver of mice 
subjected to the bacterial lipopolysaccharide (LPS) or cecum ligation and puncture (CLP) models 
of sepsis. The inflammatory induction of Sult1e1 gene by sepsis was mediated by NF-kB. 
Reciprocally, the expression and activity of Sult1e1 can impact the clinical outcome of sepsis. 
Specifically, ablation of the Sult1e1 gene or pharmacological inhibition of the Sult1e1 enzyme by 
Triclosan sensitized mice to sepsis-induced death in an estrogen dependent manner. The increased 
sepsis induced lethality in Sult1e1 knockout mice was explained to be due to increased estrogen 
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activity and the resultant attenuated sepsis-induced pro-survival inflammatory response (Chai et 
al., 2015c).  
Hepatic ischemia-reperfusion  (I/R) injury is a major cause of liver damage. The 
pathogenesis of hepatic I/R injury is a dynamic process including the deprivation of blood and 
oxygen supply during the ischemic phase, followed by their restoration during the reperfusion 
phase, which is associated with oxidative stress and inflammation. An induction of Sult1e1 in rats 
subjected to I/R was reported as early as 2006, but without a clearly defined mechanism or 
understanding of the biological significance (Svetlov et al., 2006). More recently, we reported a 
systemic analysis of the effect of liver I/R on the expression of Sult1e1. We showed that the 
expression of Sult1e1 was markedly induced by I/R in the mouse liver. The ablation of Sult1e1 
protected female mice from the injury in an estrogen dependent manner, but heightened liver injury 
in male mice in an androgen-dependent manner. Further mechanism study established Sult1e1 as 
a direct transcriptional target of nuclear factor erythroid 2-related factor (Nrf2), a key 
transcriptional factor responsible for the activation of an array of genes to adapt the cells to hypoxic 
or oxidative damages. Based on these results, we proposed that inhibition of SULT1E1, at least in 
females, may represent an effective approach to manage hepatic I/R injury (Guo et al., 2015). 
3.1.2.4 EST in cystic fibrosis 
Cystic fibrosis (CF), characterized by mutations of both copies of the cystic fibrosis 
transmembrane receptor (CFTR) gene, is an inherited disorder that causes progressive and 
eventually fatal damage to the lungs, digestive system, and other organs in the body. Liver is an 
organ that can be affected by CF. A series of papers published from the laboratory of Charles 
Falany suggested that the hepatic SULT1E1 may play a role in the progression of liver damage in 
CF patients (Li and Falany, 2007; He et al., 2008; Falany et al., 2009). Specifically, elevated 
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hepatic SULT1E1 activity was observed in mouse models of CF (Li and Falany, 2007) and HepG2 
cells co-cultured with human MMNK-1 cholangiocytes with repressed CFTR (He et al., 2008). 
The induction of SULT1E1 in CFTR-deficient MMNK-1 cells/HepG2 cells co-culture system was 
found to be dependent on the activation of LXR, and the SULT1E1 induction led to alterations in 
the expression of estrogen responsive genes, including IGF-1, GST-P1 and carbonic anhydrase II, 
due to decreased E2 levels. These results suggest that the induction of hepatic SULT1E1 in CF 
patients may have facilitated the development of CF liver disease (Falany et al., 2009). 
3.2 Hepatic estrogen sulfotransferase distantly sensitizes mice to HS-induced acute lung 
injury 
3.2.1 Research Background 
            As described in 3.1 Estrogen Sulfotransferase in liver disease, the primary function of 
EST is to sulfo-conjugate and deactive estrogens, such as estradiol. EST locates in cytosol and 
catalyzes the transfer of a negatively charged sulfonate group (SO3-) from the universal sulfate 
donor 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to a nucleophilic group of their substrates 
to generate hydrophilic products. 
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            We previously reported that the expression of EST is highly inducible in the livers of mouse 
models of multiple disease, including obesity and type 2 diabetes (Gao et al., 2012) , hepatic 
ischemia and reperfusion (Guo et al., 2015), and sepsis (Chai et al., 2015). Reciprocally, the 
expression and/or activity of EST have major effects on the outcome of these diseases through 
varied mechanisms and often in a sex- and tissue-specific manner (Gao et al., 2012; Chai et al., 
2015; Guo et al., 2015; Garbacz et al., 2017). Based on these studies, we originally hypothesized 
that EST might also impact on HS-induced hepatic injury, and we were wondering whether EST 
expression is upregulated as in other disease models and how the changes in EST expression 
impact on HS-induced hepatic injury. To this end, we employed the same mouse model of HS/R 
described in Chapter II. We also found liver EST is highly inducible in both male and female mice 
however, liver EST showed no impact on HS-induced hepatic injury as described in 3.2.3 
Experimental Results.  
Besides HS-induced liver injury, acute lung injury  is one of the leading causes of death in 
surgical and trauma patients with the in-hospital mortality rate as high as 40% (Rubenfeld et al., 
2005; Villar et al., 2014). Therefore, we are wondering if the induction of EST would play a 
pathological role in HS-induced acute lung injury. As a consequence of hemorrhagic shock and 
resuscitation (HS/R), an exaggerated inflammatory response is initiated and a large number of 
polymorphonuclear neutrophils (PMNs) are activated and migrate into the lung. The infiltration of 
PMNs is a hallmark of acute lung injury, and it plays a central role in the development of lung 
tissue injury (Liu et al., 2009; Wen et al., 2014; Xu et al., 2017). It is interesting to know whether 
liver EST would impact on inflammation response following HS and it is conceivable that a better 
understanding of the mechanism by which HS induces acute lung injury will help to develop 
effective strategies for the clinical management of HS in trauma and surgical patients. 
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Both clinical and animal studies have shown a sex-dependent response to HS. The levels 
of female sex hormones, especially 17β-estradiol, are believed to be positively associated with a 
favorable outcome after HS (Sperry et al., 2012; Yang et al., 2014). In human studies, it has been 
reported that the male sex is independently associated with 40% higher rate of multiple organ 
failure (MOF), a 25% higher rate of nosocomial infection (NI), and elevated levels of IL-6 (Sperry 
et al., 2008) in trauma patients. In contrast, the female patients tend to have lower levels of 
systemic inflammatory cytokines and they are more resistant to MOF (Frink et al., 2007). 
However, the role of estrogens in trauma patients is not without controversy. For example, it was 
reported that elevated serum levels of 17β-estradiol and testosterone in the early time period post-
injury have their independent associations with greater risk of MOF and NI (Zolin et al., 2015). In 
animal studies, it was reported that acute estradiol treatment attenuates lung inflammatory 
responses, such as reducing the basal expression of platelet endothelial cell adhesion molecule-1 
(PECAM-1) and IL-10 levels in male rats subjected to intestinal ischemia (Breithaupt-Faloppa et 
al., 2014). Treatment with 17 β-estradiol also attenuated acute lung injury induced by oxidant 
stresses other than HS, such as the herbicide paraquat and acute alveolar anoxia (Hamidi et al., 
2011). It was noted that most of the reported roles of estrogens in traumatic injury relied on the 
administration of pharmacological doses of estrogens. It is unclear whether regulation of 
endogenous estrogen metabolism can affect the clinical outcome of HS-induced tissue injury. 
Since EST is a master regulator of estrogen sulfation and deactivation and a pulmonary function 
of EST has not been reported, it is interesting to know whether and how EST plays a role in HS-
induced acute lung injury.  
In this study, we uncovered a novel function of EST in HS-induced acute lung injury. HS 
induces the hepatic expression of Est in mice. The HS-responsive induction of Est may have played 
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a pathogenic role in HS-induced acute lung injury, because genetic ablation or pharmacological 
inhibition of Est effectively protected female mice from HS-induced acute lung injury, whereas 
hepatic reconstitution of EST re-sensitized mice to HS-induced acute lung injury. 
3.2.2 Experimental Procedures 
Chemicals 
The EST inhibitor triclosan, 17β-estradiol, estrone, estrone 3-sulfate sodium salt, β-
estradiol 3-sulfate sodium salt, and dansyl chloride were purchased from Sigma-Aldrich (St. Louis, 
MO). N-butyl chloride was purchased from Fisher Scientific (Ottawa, Ontario, Canada). 17β-
estradiol-2,4,16,16,17-d5 and 17β-estradiol-2,4,16,16-d4-3-sulfate were purchased from CDN 
isotopes (Pointe-Claire, Quebec, Canada). 
Animals and mouse model of hemorrhagic shock and resuscitation 
Est-/- mice have been described previously (Qian et al., 2001). KOLE mice are Est-
knockout (KO) and Lap-EST (LE) transgenic mice that were generated by cross-breeding Est-/- 
mice with Lap-tTA/TetRE-EST (Lap-EST) transgenic mice. The Lap-EST transgene 
overexpresses the human EST exclusively in the liver/hepatocytes under the control of the liver-
enriched activator protein (Lap) gene promoter (Chai et al., 2015). All mice were maintained in 
C57/BL6 background. The majority of the experiments were performed on mice of 8 weeks of age 
except those specified for ovariectomy (5-weeks old). Hemorrhagic shock and resuscitation was 
performed as we have previously described (Xie et al., 2019), and the serum and tissues were 
collected 4, 6 or 24 hours after HS. The use of mice in this study has complied with all relevant 
federal guidelines and institutional policies, and has been approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee. 
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Bronchoalveolar lavage fluid (BALF) collection  
This was performed essentially as described (Jhingran et al., 2016). In brief, 4 hours after 
HS/R, mice were anesthetized by i.p. injections of 150 mg/kg ketamine and 10 mg/kg xylazine. A 
BALF catheter was inserted into the trachea and repeatedly injected with 0.5 ml of ice-cold PBS 
(from the “input” syringe filled with 3 ml of PBS) and then BALF was aspirated from the inflated 
lungs into the initially unfilled “output” syringe via a 3-way stopcock. We typically injected a total 
of 3 ml and recovered 2.5 ml of BALF in the output syringe. The 3-way stopcock is adjusted after 
each injection and aspiration round to ensure that BALF was captured in the output syringe. The 
recovered BALF were centrifuged at 300 g for 5 minutes. The cell free supernatants of BALF were 
collected and subjected to the measurement of protein concentration using a BCA protein assay 
kit from ThermoFisher Scientific (Waltham, MA). 
Measurement of lung wet/dry ratio 
Mice were sacrificed, and lungs were excised 4 hours after the HS/R. Blood was removed 
by blotting the lungs with filter papers until dry, and the lungs were then weighed for their wet 
weight. The lungs were subsequently placed in an oven at 65°C for 72 hours, and the dry weight 
was recorded. The wet/dry weight ratio was calculated to assess tissue edema. 
Measurement of IL-6 in BALF and serum 
These were measured using enzyme-linked immunosorbent assay kits from Pierce/Thermo 
Fisher Scientific, according to the manufacturer's instructions. 
Histology, immunohistochemistry, and immunofluorescence 
The lungs were freshly harvested and fixed in 10% neutral-buffered formalin for 24 hours. 
The tissues were histologically processed, embedded in paraffin, sectioned at 4 μm, and stained 
with hematoxylin and eosin for general histology. For myeloperoxidase (MPO) immunostaining, 
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de-paraffinized sections were incubated with anti-MPO antibody from Abcam (Cambridge, MA) 
at 1:25 dilution overnight at 4 °C. The antibody signal was visualized by peroxidase reaction using 
3,3′-diaminobenzidine as the chromogen. Hematoxylin was used as a nuclear counterstain. For 
estrogen sulfotransferase (EST) immunofluorescence, liver and lung paraffin sections were 
incubated with anti-estrogen sulfotransferase from Abcam at 1:100 dilution overnight at 4 °C. The 
secondary antibody used was a Cyanine 5 (Cy5) conjugated donkey anti-rabbit polyclonal 
antibody from MilliporeSigma (Danvers, MA) at 1:500 dilution. DAPI-Fluoromount-G purchased 
from Southern Biotech, Birmingham, AL, was used as a nuclear counterstain. For 
immunohistochemistry and immunofluorescence, at least three mice were used for each treatment 
group, and for each sample at least four noncontiguous regions were photographed and analyzed.  
Real-time PCR and Western blotting 
Real-time PCR is performed as described in Chapter II. For Western blotting, 30 μg of total 
proteins for each sample were separated on 13% SDS-polyacrylamide gel. The primary antibodies 
were polyclonal rabbit anti-SULT1E1 from Proteintech at 1:200 dilution and monoclonal mouse 
anti-β-actin from Sigma-Aldrich at 1:5000 dilution. The secondary antibodies were anti-rabbit 
antibody and anti-mouse antibody from Cell Signaling Technology at 1:5000 dilution. Detection 
was achieved by using an ECL system from Amersham (Piscataway, NJ). 
Flow cytometry  
Tissue dissection and digestion were performed as described (Jhingran et al., 2016). Mouse 
bone marrow neutrophils were isolated and purified as described (Swamydas and Lionakis, 2013). 
Flow cytometry was performed as described (Liu et al., 2009; Jhingran et al., 2016). In brief, 200 
μL suspended cells (approx. 2.5 million cells) or 100ul peripheral blood were stained with anti-
CD45 buv395, anti-CD11b-APC antibody, anti-Gr-1-PE antibody, and anti-CXCR2(CD182)-
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FITC antibody for the detection of neutrophils. The stained cells were applied for data acquisition 
on BD STI LSRII Cytometer and re-analyzed with BD FACSDIVA software. 
Estradiol extraction and derivatization  
Estradiol was extracted by liquid-liquid extraction using n-Butyl chloride and then 
derivatized with dansyl chloride as previously described by Li, et al (Li et al., 2016). Samples were 
first spiked with internal standard 20 μL17β-estradiol-2,4,16,16,17-d5 (1 ng/ml in methanol). 3 ml 
n-Butyl chloride was then added and vortexed for 1 min. The tubes were then centrifuged at 4770g 
at room temperature for 10 min and the organic layer was transferred to salinized culture tubes and 
dried down under a soft steam of nitrogen at 37 °C for 20 min. Residues were derivatized in 0.1 
ml buffered dansyl chloride solution (a 1:1 mix of acetonitrile: water, pH 10.5), heated at 60 °C 
for 3 min, and then transferred to glass vials for UPLC-MS/MS analysis. 
Estradiol sulfate extraction  
Estrogen sulfates in lung tissue were extracted in 75% methanol before drying down. 
Sediment were removed after recovering with 1 ml PBS and centrifuging for 20 min (8000 g, 4 
°C). For both lung tissue samples and serum samples, internal standard 17β-estradiol-2,4,16,16-
d4-3-sulfate (100 pg) were added. Solid-phase extraction using Oasiss MCX (3 cc/60 mg, Waters) 
extraction cartridges was performed under gravity. Prior to loading the tissue or serum samples, 
the cartridges were conditioned with methanol (1 ml), followed by water (1 ml). The sample was 
loaded and allowed to pass through the cartridges and the eluate discarded. Next, the cartridges 
were washed with methanol (5% v/v, 3 ml) and again the eluate discarded. Finally, the estrogen 
sulfates were eluted in methanol (3 ml). Extracts were reduced to dryness under oxygen-free 
nitrogen at 40 °C. 
UPLC–MS/MS analysis of estradiol and estradiol sulfate  
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We used published UPLC–MS/MS methods for the detection of estradiol (Li et al., 2016) 
and estradiol sulfate (Chai et al., 2015) with minor modifications. Liquid chromatography was 
performed using an Acquity ultra performance LC autosampler from Waters (Milford, MA). 
Analytes were separated on a UPLC BEH C-18, 1.7 mm (2.1 × 150 mm) reverse-phase column 
from Waters. Column temperature was maintained at 55 °C. For estradiol detection, mobile phases, 
delivered at a flow rate of 0.3 ml/min, consisted of (A) acetonitrile and (B) 0.1% formic acid in 
water, at an initial mixture of 50:50 A and B. Mobile phase B was maintained at 50% for 1 min 
and then increased to 85% in a linear gradient over 3 min, where it remained for 1 min. This was 
followed by a linear return to initial conditions over 1.5 min. For the detection of estradiol sulfate, 
mobile phase B was maintained at 80%. Total run time per sample was 6.5 min and all injection 
volumes were 7.5 l. Mass spectrometric analysis of analyte formation was performed using a 
TSQ Quantum Ultra from Thermo Fisher Scientific (San Jose, CA) triple quadrupole mass 
spectrometer coupled with heated electrospray ionization source (HESI) operated in negative 
selective reaction monitoring (SRM) mode with unit resolutions at both Q1 and Q3 set at 0.70 full 
width at half maximum. Quantification by SRM analysis of estradiol and estradiol sulfate were 
performed by monitoring the m/z transitions. 
PMNs isolation from bone marrow 
This experiment was performed as described (Swamydas et al., 2015).  In brief, PMNs 
were isolated and purified from bone marrow cells using Histopaque-based density gradient 
centrifugation. 3 ml of Histopaque 1077 (density, 1.077 g/ml) were overlaid on 3 ml of Histopaque 
1119 (density, 1.119 g/ml) in a 15-ml conical centrifuge tube, and the bone marrow cell suspension 
were added on top of the Histopaque 1077 layer. Collect the neutrophils at the interface of the 
Histopaque 1119 and Histopaque 1077 layers after centrifuging for 30 minutes at 872 × g at room 
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temperature without brake. The collected PMNs were washed twice with RPMI 1640 1X 
supplemented with 10% FBS and 1% penicillin/streptomycin and centrifuged at 1400 rpm for 7 
minutes at 4°C before cell plating. 
Statistical analysis 
Results are expressed as mean  SE. Differences between two individual groups were 
determined by Student’s t test. Differences between multiple groups were evaluated using two-
way analysis of variance followed by post-hoc multiple comparison according to the Tukey’s test. 
Statistical significance was accepted at p  0.05. 
3.2.3 Experimental Results 
3.2.3.1    Hemorrhagic shock (HS) tissue specifically induces the expression of Est in the 
liver 
To determine whether liver EST is inducible after HS, we performed the same HS model 
here and harvested the tissue at 24 h after HS. We found the mRNA expression of Est was 
markedly induced in the liver, but not in the lung of female mice subjected to HS/R (Figure 22A). 
HS/R also induced the mRNA expression of Est in male mice, but the fold induction was not as 
dramatic as in female mice (Figure 22B). The induction of Est protein in the liver and lack of 
induction in the lung of female and male mice were further verified by immunofluorescence 
(Figure 22C). The expression of Est in the lung was barely detectable, consistent with a previous 
report (Riches et al., 2009). The HS/R-responsive inductions of Est protein in the liver of female 
and male mice were also confirmed by Western blotting (Figure 22D).  
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Figure 22. Hemorrhagic shock (HS) specifically induces the expression of Est in the liver. 
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Female and male WT mice were subjected to Sham surgery or HS/R. Serum and tissue were harvested at 24 hours 
after HS. (A and B) The mRNA expression of Est in the liver and lung of female (A) and male (B) mice was measured 
by real-time PCR. (C) The protein expression of Est in the liver and lung in female and male mice was measured by 
immunofluorescence staining of DAPI (blue) and Est (green). Bar is 100 μm. (D) The protein expression of Est in the 
liver of female and male mice was measured by Western Blotting. Shown to the right is the quantification of the 
Western results. Numbers in parentheses in A and B are average real-time PCR cycle numbers. Results are presented 
as mean SE. n=3 for each group. *, p < 0.05; **, p < 0.01, compared to the Sham groups.  
Because of the significant induction of liver Est after HS/R surgery, we sought to know if 
the induction of liver Est play a pathological role in HS-induced hepatic injury similar to the 
diseased models we reported before. To our surprise, Est ablation in female mice had little effect 
on hepatic injury at different time points after HS. Here showing is the liver histology at 24 h after 
HS (Figure 23A) and serum level of alanine aminotransferase (ALT) (Figure 23B). 
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Figure 23. Est ablation has no effect on HS-induced hepatic injury. 
Female WT and Est-/- mice were subjected to HS/R. Mice were sacrificed 24 hours after the initiation of HS. (A) H&E 
the liver sections (left) and quantification of the necrotic areas (right). The Ns within the dotted circle indicate the 
necrotic areas. Bar is 100 μm. (B) Serum levels of ALT. Results are presented as mean SE. n=4~5 for each group. 
*, p < 0.05; **, p < 0.01, with the comparisons labeled.  
 
3.2.3.2 Genetic ablation or pharmacological inhibition of Est protects female, but not male 
mice from HS-induced acute lung injury 
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Since lung is sensitive to HS-induced acute immune responses which participants tissue 
injury immediately after HS, we measured acute lung injury at different time points, including 4 
or 24 hours after HS in female wild-type (WT) and Est-/- mice to determine the functional relevance 
of Est induction in HS-induced acute lung injury. The liver expression of Est was efficiently 
induced at both time points (Figure 24). When acute lung injury was evaluated, female Est-/- mice 
were found to be protected from HS-induced acute lung injury at both time points, including 
decreased pulmonary interstitial edema and infiltration of cells into the interstitium and alveolar 
spaces at the histological level (Figure 25A), decreased bronchoalveolar lavage fluid (BALF) 
protein concentrations, a marker for tissue leakage (Figure 25B), and decreased lung wet to dry 
(W/D) ratio, the marker for water retention, (Figure 25C). In an independent model of 
pharmacological inhibition of Est, treatment of female WT mice with the EST inhibitor triclosan 
(5-chloro-2(2,4-dichlorophenoxy)-phenol) (Wang et al., 2004) also inhibited the 4-hour HS-
induced acute lung injury, as shown by histology (Figure 25D) and measurements of BALF protein 
concentration (Figure 25E) and W/D ratio (Figure 25F). Interestingly, we noticed triclosan 
treatment itself tended to induce an increase in BALF protein and W/D ratio in the sham condition 
(Figure 25E and 25F). It has been reported that triclosan can trigger colonic inflammation in mice, 
so it is possible triclosan may have also induced mild inflammation in the lung and caused a mild 
induction of the total BALF protein level in the sham group. However, the inhibition of EST by 
triclosan which results in the elevation of estrogens overrided the pro-inflammatory activity of 
triclosan, leading to an overall protective effect, including decreased total protein in BALF.  
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Figure 24. Expression of liver Est at different time point following HS/R. 
The mRNA expression of Est was measured by real-time PCR. Results are presented as mean SE. n=4~5 for each 
group. *, p < 0.05; **, p < 0.01, compared to the Sham group.  
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Figure 25. Genetic ablation or pharmacological inhibition of Est protects female, but not male mice from HS-
induced acute lung injury. 
(A-C) Female WT and Est-/- mice were subjected to HS/R. The mice were sacrificed 4 or 24 h after the initiation of 
HS. Shown are H&E staining of the lung sections (A, Bar is 100 μm). The section shows interstitial edema and 
infiltrated blood cells in the lung tissue (arrow-head). Protein concentrations in the cell free bronchoalveolar lavage 
fluid (BALF) (B), and wet/dry (W/D) weight ratio of the lung tissues (C) were also shown. (D-F) Female WT mice 
were subcutaneous injected daily with triclosan (10 mg/kg) beginning 3 days before HS/R surgery. Mice were 
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sacrificed 4 h after the initiation of HS. Shown are H&E staining of the lung sections (D, original magnification 200x), 
BALF protein concentrations (E), and lung W/D ratio (F). Results are presented as mean SE. n=4-5 for each group. 
*, p < 0.05; **, p < 0.01, with the comparisons among groups as labeled (B, C, E and F).  
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3.2.3.3 The pulmonoprotective effect of Est ablation is estrogen dependent 
Consistent with the notion that a primary function of EST is to sulfonate and deactivate 
estrogens, we found the circulating (Figure 26A) and lung tissue (Figure 26B) levels of estradiol 
were elevated in sham-treated female Est-/- mice. In contrast, the circulating level of estradiol 
sulfate was decreased in sham-treated female Est-/- mice (Figure 26C). The dropped levels of 
estradiol and estradiol sulfate in 4-hour HS-treated Est-/- mice were likely accounted for by the 
withdrawal of a large volume of blood during HS, and insufficient time to replenish estrogens 
within 4 hours before the mice were sacrificed. Consistent with the increased lung tissue 
concentration of estradiol, the pulmonary expression of the estrogen-responsive gene Areg, 
encoding the amphiregulin protein (Deroo et al., 2009), was increased in Est-/- mice subjected to 
sham surgery (Figure 26D). Since estrogens are known for their pulmonoprotective effect 
(Breithaupt-Faloppa et al., 2014), we speculated that the elevated circulating and lung tissue 
estrogen levels might have accounted for the pulmonoprotective phenotype in the female Est-/- 
mice. To evaluate the estrogen dependence, we performed ovariectomy (OVX) on female Est-/- 
mice before subjecting them to HS/R. Indeed, OVX attenuated the pulmonoprotective phenotype 
as shown by histology (Figure 26E), and measurements of BALF protein concentration (Figure 
26F) and lung W/D ratio (Figure 26G), suggesting that the pulmonoprotective effect of Est ablation 
was estrogen dependent.  
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Figure 26. The pulmonoprotective effect of Est ablation is estrogen dependent. 
(A-D) Mice are the same 4-h HS/R mice described in Fig. 2A. Shown are serum estradiol levels (A), lung estradiol 
levels (B), serum estradiol sulfate levels (C), and pulmonary mRNA expression of Areg (D). (E-G) Female Est-/- mice 
were subjected to sham surgery or ovariectomy (OVX) at 5 weeks old before being subjected to sham surgery or HS/R 
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when the mice were 8 weeks old. Mice were sacrificed 4 h after the initiation of HS. Shown are H&E staining of the 
lung sections (E, original magnification 200x). The section shows interstitial edema and infiltrated blood cells in the 
lung tissue (arrow-head). BALF protein concentrations (F), and lung W/D ratio (G) were also shown. Results are 
presented as mean SE. n=4-5 for each group. *, p < 0.05; **, p < 0.01, with the comparisons labeled. 
 
Interestingly, treatment of female Est-/- mice with Fulvestrant, an ER/ antagonist that 
destabilizes ER (Casa et al., 2015; Gorska et al., 2016; Win et al., 2019), failed to abolish the 
pulmonoprotective effect as shown by histology (Figure 27A) and measurements of BALF protein 
concentration (Figure 27B) and W/D ratio (Figure 27C). As expected, the pulmonary mRNA 
expression of Areg was inhibited by Fulvestrant (Figure 27D). These results suggested that 
although the protective effect of Est ablation was estrogen dependent, it might be ER independent. 
Hemorrhagic shock had little effect on the pulmonary expression of other enzymes involved in the 
local estrogen homeostasis, such as aromatase (Cyp19a1) (Figure 28A), 17β-hydroxysteroid 
dehydrogenase (HSD) 17β1 (Hsd17b1) (Figure 28B), and steroid sulfatase (Sts) (Figure 28C), 
regardless of the Est genotypes.  
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Figure 27. Treatment with the ER antagonist Fulvestrant fails to re-sensitize Est-/- mice to HS-induced acute 
lung injury. 
 (A to D) Female Est-/- mice were weekly and subcutaneously injected with Fulvestrant (5 mg/kg) for 3 weeks before 
being subjected to the Sham surgery or HS/R.  Mice were sacrificed 4 h after the initiation of HS. Shown are H&E 
staining of the lung sections (A, with arrowheads indicating interstitial edema and cell infiltrations, original 
magnification 200x), BALF protein concentrations (B), and lung W/D ratio (C), and pulmonary mRNA expression of 
Areg (D). Results are presented as mean SE. n=4~5 for each group. *, p < 0.05; **, p < 0.01, with the comparisons 
labeled.  
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Figure 28. Local estrogen synthesis in the lung is not affected by HS/R. 
(A-C) The mRNA expression of genes related to estrogen synthesis, Cyp19a1 (A), Hsb17b1 (B), and Sts (C) was 
measured by real-time PCR. Results are presented as mean SE. n=3 for each group.  
3.2.3.4 Reconstitution of EST to the liver abolishes the pulmonoprotective effect of Est 
ablation 
Since the expression of Est in the lung was barely detectable and it was not inducible by 
HS/R, we speculated that the phenotype in female Est-/- mice may have resulted from the loss of 
Est in an extrapulmonary tissue. Knowing that hepatic expression of Est was induced by HS/R in 
WT mice, we wanted to determine whether EST in the liver played a pathogenic role in HS-
induced acute lung injury. For this purpose, we generated the KOLE mice that are Est knockout 
(KO) and Lap-EST (LE) transgenic. The KOLE mice were generated by breeding the liver-specific 
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Lap-EST transgene (18) into the Est-/- background as outlined in Figure 29A. The LE transgenic 
mice express the human EST/SULT1E1 exclusively in the liver under the control of the liver-
enriched activator protein (Lap) gene promoter (Chai et al., 2015). The reconstitution of EST in 
the liver, but not in the lung, was verified by Western blotting (Figure 29B). Compared to the acute 
lung injury resistant female Est-/- mice, the female KOLE mice showed sensitivity to HS/R-induced 
acute lung injury, as evidence by their increased pulmonary interstitial edema (Figure 29C), BALF 
protein contents (Figure 29D), and lung W/D ratio (Figure 29E). Consistent with their 
reconstitution of EST, the sham-treated female KOLE mice showed decreased levels of serum 
(Figure 29F) and lung tissue (Figure 29G) estradiol, and an increased circulating level of estradiol 
sulfate (Figure 29H) compared to their Est-/- counterparts.  
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Figure 29. Reconstitution of EST to the liver abolishes the pulmonoprotective effect of Est ablation. 
(A) Schematic representation of the creation of the KOLE transgenic mice. (B) Expression of EST in the liver and 
lung as measured by Western blotting. (C-H) Female Est-/- and KOLE mice were subjected to the Sham surgery or 
HS/R. Mice were sacrificed 4 h after the initiation of HS. Shown are H&E staining of the lung sections (C, original 
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magnification 200x). The section shows interstitial edema and infiltrated blood cells in the lung tissue (arrow-head). 
BALF protein concentrations (D), lung W/D ratio (E), serum estradiol levels (F), lung estradiol levels (G), serum 
estradiol sulfate levels (H) were also shown. Data of estradiol and estradiol sulfate levels in Est-/- mice are from the 
same mice in Figure 23. Results are presented as mean SE. n=4-5 for each group. *, p < 0.05; **, p < 0.01, with the 
comparisons labeled. 
3.2.3.5 Est ablation attenuates, whereas liver reconstitution of EST restores HS-induced 
lung local and systemic inflammation 
Estrogens are known for their anti-inflammatory activities. To determine whether the 
inhibition of HS-induced acute lung injury in female Est-/- mice was accompanied by the 
attenuation of inflammation, we evaluated pulmonary infiltration of PMNs, another hallmark of 
acute lung injury (Matute-Bello et al., 2008), by measuring the number of lung PMNs by flow 
cytometry and the level of myeloperoxidase (MPO) by immunohistochemistry. Myeloperoxidase 
is a widely used index of polymorphonuclear neutrophil sequestration that reflects the infiltration 
of lung parenchymal phagocytes (Bradley et al., 1982). Since PMNs is the most abundant cell type 
included in CD45+/CD11b+/Gr-1+ myeloid cells, we used CD11b and Gr-1 as markers representing 
PMNs infiltration in this current study. Compared to HS-treated female WT mice, HS-treated 
female Est-/- mice showed a reduced level of lung CD45+/CD11b+/Gr-1+ cells as shown by flow 
cytometry (Figure 30A) and its quantification (Figure 30B), as well as MPO immunostaining 
(Figure 30C), and these effects were abolished in ovariectomized Est-/- mice and intact KOLE mice 
(Figure 30A-30C). Consistent with the results of flow cytometry and histology, the reductions in 
the pulmonary mRNA expression of ICAM-1 (Figure 30D) and IL-6 (Figure 30E), and in the serum 
(Figure 30F) and BALF (Figure 30G) levels of IL-6 observed in HS-treated female Est-/- mice were 
attenuated or abolished in ovariectomized Est-/- mice or intact KOLE mice. ICAM-1 contributes 
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to the firm adhesion and emigration of PMNs (Bullard et al., 1995), whereas IL-6 is known to 
regulate neutrophil trafficking and function (Fielding et al., 2008). One exception is that 
ovariectomy did not increase the BALF IL-6 level, suggesting that there might be other yet to be 
identified substrates or metabolites of Est that may have also contributed to the protective effect 
Est ablation. 
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Figure 30. Est ablation attenuates, whereas liver reconstitution of EST restores HS-induced lung local and 
systemic inflammation. 
(A and B) Polymorphonuclear neutrophils (PMN) were quantified by flow cytometry in the lung collected from 
female WT, Est-/-, Est-/- OVX, and KOLE mice subjected to the Sham surgery or HS/R. Mice were sacrificed 4 h after 
the initiation of HS. Shown are gating strategy (upper three panels) and representative density plots (bottom panels) 
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of flow cytometry (A) and quantification of lung CD45+/CD11b+/Gr-1+ PMN cells normalized by PMNs in Sham 
group (B). (C) Myeloperoxidase (MPO) immunohistochemical staining on lung paraffin sections. Arrowheads 
indicate positive MPO staining. Original magnification 200x. (D and E) The mRNA expression of ICAM-1 (D) and 
IL-6 (E) was measured by real-time PCR. (F and G) The serum (F) and BALF (G) levels of IL-6 were measured 
ELISA. Results are presented as mean SE. n=4~5 for each group. *, p < 0.05; **, p < 0.01, with the comparisons 
labeled.  
3.2.3.6 Est ablation attenuates HS-induced PMN mobilization from the bone marrow 
Besides the PMN migration to the lung, we also wondered whether Est ablation also 
affected HS-responsive mobilization of PMNs from the bone marrow (BM) to the circulation. To 
this end, we  went on to measure the numbers of PMNs in peripheral blood and BM collected at 
multiple time points including 4 and 6 hours after HS by flow cytometry. Based on our result 
(Figure 31), the change of PMNs peaks at 6 hours after HS rather than 4 hours after HS in WT 
mice, indicating the release of PMNs from the BM to peripheral blood happens later than the 
recruitment of PMNs to the lung tissue. Therefore, we continued to measure the changes of PMNs 
at 6 hours after HS in both WT and Est-/- mice. 
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Figure 31. Dynamic changes of PMNs in blood and BM after HS. 
Consistent with their attenuation of acute lung injury, HS-treated Est-/- mice showed 
reduced PMNs mobilization as shown by decreased PMN induction in peripheral blood (Figure 
31A and 31B) and attenuated PMN reduction in BM (Figure 31C and 31D) as compared to WT 
mice at 6 hours after HS. We observed a slightly higher level of blood PMNs in Est-/- mice than 
WT mice in the sham group. As reported by others, there is an unresolved paradox with respect to 
the immunomodulating role of estrogens, either suppression of inflammation during trauma and 
sepsis or the pro-inflammatory effects in some chronic autoimmune diseases in humans. It has 
been suggested that E2 can stimulate the expression and secretion of IL-1 and IL-6 in certain cell 
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or tissue types (35). Future studies are necessary to further define the role of EST and estradiol in 
HS-induced lung inflammation. The C-X-C chemokine receptor type 2 (CXCR2) is an important 
PMN surface receptor that contributes to PMN release from BM (Eash et al., 2010). There was a 
5-fold induction of CXCR2 positive PMNs in the peripheral blood of HS-treated WT mice, but 
this induction was abolished in HS-treated Est-/- mice (Figure 31E), further suggesting that Est 
ablation inhibited the mobilization of PMN from BM. CXCR4, a chemokine receptor important 
for PMNs retention in BM was also measure by flow cytometry (data is not shown)(Martin et al., 
2003). However, no significant correlation between Est and CXCR4 positive PMNs was found. 
 
Figure 32. Est ablation attenuates HS-induced PMN mobilization from the bone marrow. 
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(A-D) PMNs in peripheral blood and bone marrow (BM) of female WT and Est-/- mice subjected to HS/R are 
quantified by flow cytometry. Mice were sacrificed 6 h after the initiation of HS. Shown are representative density 
plots (A) and quantification of CD45+/CD11b+/Gr-1+ PMN cells normalized by PMNs in Sham group (B) in peripheral 
blood, as well as representative density plots (C) and quantification of CD45+/CD11b+/Gr-1+ PMN cells normalized 
by PMNs in Sham group (D) in BM. (E) Quantification of CXCR2+ PMNs in peripheral blood by flow cytometry. 
Results are presented as mean SE. n=3 for each group. *, p < 0.05; **, p < 0.01, with the comparisons labeled. 
3.2.4 Discussion and Conclusion 
Hemorrhagic shock remains a major health concern largely due to the secondary tissue and 
organ injuries. A better understanding of the pathophysiology of HS and the mechanisms by which 
HS induces tissue injury, including lung injury, will help to develop better therapeutic strategies 
to reduce the morbidity and mortality of HS. In this study, we have uncovered a novel function of 
liver EST in HS-induced acute lung injury.  
One of our interesting findings was the estrogen dependence and sex-specific effect of Est 
inhibition on HS-induced acute lung injury. Sex-specific differences in pulmonary morbidity in 
humans have been well documented. The mortality of acute lung injury was higher in male patients 
compared to female patients (Sperry et al., 2012; Yang et al., 2014). The female protection was 
postulated to be due to the protective effect of estrogens in pre-menopausal patients (Staren and 
Omer, 2004; Sperry et al., 2008; Yang et al., 2014), a notion consistent with our finding that the 
female Est-/- mice were protected from HS-induced acute lung injury and this protection was 
estrogen dependent. Knowing ER mediates many of the estrogen functions, we were surprised to 
find that treatment with the ER/ antagonist Fulvestrant had little effect on the pulmonoprotective 
effect of Est ablation, suggesting the protection was ER independent. Estrogens are known to exert 
their functions through multiple pathways in either an ER dependent or independent manner (Hall 
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et al., 2001; Yue et al., 2013). Future use of ER α and/or β knockout mice will further clarify the 
role of ER in mediating the EST effect. Most of the reported roles of estrogens in traumatic injury 
relied on the administration of pharmacological doses of estrogens. Our results suggested that the 
benefit of estrogens in organ protection can also be achieved through the regulation of endogenous 
estrogen homeostasis, such as that mediated by EST and its regulation. Modulation of estrogen 
activity by regulating the metabolism of endogenous estrogens has the potential benefit of avoiding 
side effects associated with pharmacological estrogen therapies (Staren and Omer, 2004).  
The inhibition of PMN mobilization from BM by Est ablation was also interesting. The 
HS-responsive mobilization of PMNs from BM was at least in part contributed to by the induction 
of CXCR2, a chemokine receptor important for PMN release from BM. The HS-responsive 
induction of CXCR2 positive PMNs was abolished in Est-/- mice, which may have contributed to 
the inhibition of PMN mobilization. The effect of Est on the number of CXCR2 positive PMNs 
was unlikely intrinsic, because PMNs isolated from BM had no detectable expression of Est (data 
not shown). Rather, the induction of CXCR2 positive PMNs may have been explained by the 
induction of hepatic Est and decreased circulating level of estrogens, because CXCR2 is known to 
be negatively regulated by estradiol (Lei et al., 2003; Lasarte et al., 2016). Based on literature 
studies, we were suspecting that estrogens might influence the expression, translocation or intrinsic 
activity of G protein-coupled receptor kinase (GRK) (probably GRK-2, or 6), and thereby 
mediating the desensitize and internalize of the CXCR2 (Raghuwanshi et al., 2012; Miyoshi et al., 
2013). However, more studies are needed to build the link between circulating estrogens and the 
expression of CXCR2 on PMNs. 
Interestingly, ablation of Est had little effect on HS-induced acute lung injury in male mice. 
The mechanism for the lack of pulmonoprotective effect in male Est-/- mice remains to be 
 83 
understood. Est ablation had little detectable effect on the circulating and lung tissue levels of 
estrogens in male mice, which may be due to the extremely low levels of endogenous estrogens 
that were beyond the detections by LC/MS (data not shown). Nevertheless, the sex-specific effect 
of EST was not uncommon. Sex-specific effects of Est ablation were also observed in our previous 
studies of metabolic disease and liver ischemia-reperfusion induced liver injury. We reported that 
Est ablation protected female ob/ob (leptin deficient, or Lepob) mice from obesity and type II 
diabetes, but sensitized male ob/ob mice to metabolic syndrome (Gao et al., 2012). In a mouse 
model of liver ischemia-reperfusion, Est ablation conferred hepatoprotection to female mice, 
whereas the male Est-/- mice were further sensitized (Guo et al., 2015). Interestingly, unlike in the 
ob/ob mice or in the liver ischemia-reperfusion models, Est ablation did not sensitize male mice 
to HS-induced acute lung injury. 
Another interesting finding was the evidence of organ crosstalk and the tissue-specific 
effect of EST on HS-induced acute lung injury. Different from liver I/R which blocks the blood 
flow in the liver and resulted in the damage primarily in the liver, HS is a systemic condition of 
deprivation of blood and impact on multiple organs including lung, liver and etc. Similar to liver 
I/R, HS significantly induces liver Est, however, Est ablation surprisingly had little effect on HS-
induced hepatic injury. The lack of Est knockout effect on HS-induced hepatic injury was 
reminiscent of the lack of effect of Est ablation on obesity and type 2 diabetes, despite a marked 
hepatic induction of this enzyme in metabolic disease (Gao et al., 2012; Garbacz et al., 2017). An 
even more interesting finding is that the hepatic EST can distantly sensitize mice to HS-induced 
acute lung injury, which was supported by two key pieces of evidence: 1) There was no appreciable 
expression or induction of Est in the lung in response to HS; and 2) Reconstitution of EST to the 
liver of KOLE mice was sufficient to re-sensitize female Est-/- mice to HS-induced acute lung 
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injury. The distal effect of hepatic EST on HS-induced acute lung injury was likely mediated by 
hepatic metabolism of estrogens, which led to decreased circulating and lung tissue levels of active 
estrogens. The lack of HS effect on the pulmonary expression of other enzymes involved in local 
estrogen homeostasis suggested that the increased estrogen activity in the lung was independent 
of local estrogen production. 
In summary of Chapter III (Figure 32), we have uncovered a novel contribution of liver 
EST to HS-induced acute lung injury. EST has been shown to affect the structure and function of 
several tissues, including the male and female reproductive tissues, liver, and adipose tissue. To 
our best knowledge, the current study represents the first report on the pulmonary function of EST, 
and the pulmonary effect of EST was achieved via the liver-to-lung organ crosstalk. Our results 
suggested that pharmacological inhibition of EST, at least in females, might represent a novel 
therapeutic approach to manage HS-induced acute lung injury. 
 
Figure 33. Summary of Chapter III. 
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4.0 Summary and Perspectives 
Over the past 50 years or so, significant advances have been achieved in our emergency 
management of HS. Despite of the development of modern resuscitation techniques which led to 
an improved immediate survival, the occurence of subsequent organ failure remains a major health 
issue that may lead to late death (Minei et al., 2012). Among HS-induced tissue injuries,  hepatic 
injury and acute lung injury are of high incidence (Yu et al., 2008; Wetzel et al., 2014). Acute lung 
injury is also one of the leading causes of death in surgical and trauma patients with the in-hospital 
mortality rate as high as 40% (Rubenfeld et al., 2005; Villar et al., 2014). The pathogenesis of HS-
induced tissue injury is dynamic, including the deprivation of blood and oxygen supply in the acute 
phase, followed by blood volume restoration upon resuscitation, or re-establishment of the 
circulation, which resulted in exaggerated inflammatory responses and oxidative stress. A better 
understanding of the mechanism by which HS induces tissue injury will help to develop effective 
strategies for the clinical management of HS in trauma and surgical patients, here we conducted 
mechanism studies on HS-induced hepatic injury and acute lung injury. 
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Figure 34. Overall Summary 
As summarized in Figure 29, in Chapter II we have investigated the role of PXR in the 
setting of HS-induced hepatic injury. Since PXR is a species-specific xenobiotic receptor that 
regulates the expression of DMEs with CYP3A as its primary target gene (Yan and Xie, 2016) and 
seriously injured trauma patients are often prescribed with medications that can activate PXR and 
induce CYP3A, including DEX as an ICU medication, fibrates for trauma patients with 
hyperlipidemia, and the antibiotic RIF for reducing deep surgical site infections (Shiels et al., 2018; 
Tyas et al., 2018) or for the treatment of tuberculosis. We focused our study on whether and how 
the activation of PXR plays a role in HS-induced hepatic injury. Through utilizing different 
pharmacologic and genetic mouse models, we showed that activation of PXR sensitized mice to 
HS-induced hepatic injury in a CYP3A-dependent manner. The sensitizing effect of PXR on HS-
induced hepatic injury can be mitigated by inhibition of CYP3A, or treatment with an antioxidant, 
or a PXR antagonist. However, manipulation of PXR had little impact on HS-induced acute lung 
injury. The lack of impact of PXR on HS-induced acute lung injury might because the extremely 
low expression of PXR in the lung. 
(Chapter II) 
(Chapter III) 
 87 
As described in Chapter III, we investigated the role of EST in the setting of HS-induced 
acute lung injury. At the beginning, we were expecting ablation of Est would also show a primary 
protective effect on HS-induced hepatic injury similar to the results in other liver injury/disease 
models, including sepsis (Chai et al., 2015), liver I/R (Guo et al., 2015), type II diabetes (Gao et 
al., 2012), reported in our previous studies since we observed a significant upregulation of  Est 
expression by HS. However, limited protective effect on liver in Est-/- mice subjected to HS were 
found. In contrast, a significant pulmonoprotective effect was observed in Est-/- mice as early as 4 
hours after HS surgery, even though Est expression was barely detectable in the lung. On the other 
hand, hepatic reconstitution of EST re-sensitized mice to HS-induced ALI. Besides tissue-specific 
effect, we also demonstrated the sex-specific effect of EST on the outcome of HS-induced acute 
lung injury. Only female mice responded to Est ablation associated pulmonoprotective effect. 
Further mechanism study established a link between EST and the mobilization/migration of PMNs 
into lung following HS mediated by the changes in circulating estrogens, especially 17β-estradiol. 
The ablation or inhibition of EST resulted in the elevated circulating level of 17β-estradiol, which 
is believed to be positively associated with a favorable outcome with attenuated lung inflammation 
after HS (Sperry et al., 2012; Breithaupt-Faloppa et al., 2014; Yang et al., 2014), and thereby 
reducing the mobilization/migration of PMNs following HS. 
Besides mechanisms discussed in this dissertation study, a complex cascade of 
posttraumatic events related to inflammatory and immune responses, such as complement 
activation(Younger et al., 2001), contribute the adverse immune consequences of HS. Autophagy 
can also be induced under stress conditions, which on one hand facilitates cell survival by 
removing damaged subcellular debris and on the other hand triggers cell death pathways through 
apoptosis (He and Simon, 2013). Although the current study provides novel insights into the roles 
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of PXR and EST in HS-induced tissue injury, more studies are needed to take more comprehensive 
mechanisms into consideration, such as 1) complement activation, autophagy, and their causal 
relationship with PXR and/or EST; 2) the identification of previously unknown molecular 
mechanisms underlying the roles of PXR and EST in impacting tissue damage and establishing 
the link between EST/estrogen signaling and surface CXCR2 expression on neutrophil; 3) the 
crosstalk between PXR or EST and toll-like receptors (TLRs), TLR4 and TLR2, who have been 
demonstrated to be key factors impacting tissue injury induced by HS (Li et al., 2009; McDonald 
et al., 2015; Ding et al., 2017) and sepsis (Chai et al., 2015); as well as 4) the crosstalk between 
PXR and other nuclear receptors, such as liver X receptor (LXR) and constitutive androstane 
receptor (CAR). 
 In summary, in this dissertation study, we uncovered novel functions of PXR and EST in 
HS-induced tissue injuries in a tissue-specific manner. PXR and EST work through different 
mechanisms in HS-induced tissue injuries, 1) PXR works as a xenobiotic transcription factor 
mediating the induction of CYP3A which contributes to HS-induced hepatic injury, but not acute 
lung injury, through the generation of ROS; 2)  Liver EST works as an enzyme catalyzing the 
sulfation and deactivation of estrogens which distantly impacts on HS-induced lung injury via the 
recruitment of PMNs to the lung, whereas lack of impacts on HS-induced hepatic injury. Despite 
of the different mechanisms of PXR and EST in HS-induced tissue injury, both of them are master 
regulators that control the exogenous and endogenous metabolism, and they are the potential 
therapeutic targets in preventing of HS-induced tissue injury. Clinical studies are urgently needed 
for the clinically evaluation of the effectiveness of PXR and EST antagonists or inhibitors in HS 
patients. 
 89 
Appendix A  
Table 1. Oligonucleotide sequences of primers used for real-time PCR 
Gene Name NCBI Reference Sequences 
mEst NM_023135.2 
Forward: 5’- GGAACGCCAAAGATGTCGCCG -3’ 
Reverse: 5’- ACCATACGGAACTTGCCCTTGCA -3’ 
mIcam-1 NM_010493.3 
Forward: 5’- TTCACACTGAATGCCAGCTC -3’ 
Reverse: 5’- GTCTGCTGAGACCCCTCTTG -3’ 
mCyp19a1 NM_001348171.1 
Forward: 5’- AGCCTGTTGTGGACTTGGTC -3’ 
Reverse: 5’- ACTCGAGCCTGTGCATTCTT -3’ 
mIl-6 NM_031168.2 
Forward: 5’- CGACGGCCTTCCCTACTT -3’ 
Reverse: 5’- TGGGAGTGGTATCCTCTGTGAA -3’ 
mAreg NM_009704.4 
Forward: 5’- TGGCAGTGAACTCTCCACAG -3’ 
Reverse: 5’- CAATTGCATGTCACCACCTC -3’ 
mSts NM_009293.1 
Forward: 5’- GCTCGTCTACTTCACCTCGG -3’ 
Reverse: 5’- GTGGGGAAGACGTCCATGAG -3’ 
mCyclophilin NM_011149.2 
Forward: 5’- GGCTCCGTCGTCTTCCTTTT -3’ 
Reverse: 5’- TGACACGATGGAACTTGCTGT -3’ 
mCyp3a11 NM_007818.3 
Forward: 5’- AGGGAAGCATTGAGGAGGAT -3’ 
Reverse: 5’- GGTAGAGGAGCACCAAGCTG -3’ 
mCyp2b10 NM_009999.4 
Forward: 5’- CGCATGGAGAAGGAGAAGTC -3’ 
Reverse: 5’- CTCTGCAACATGGGGTACT -3’ 
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mCyp2c29 NM_007815.3 
Forward: 5’- CATGCAAGACAGGAGCCACA -3’ 
Reverse: 5’- CTGCATCAGGCAGGCTAGTG -3’ 
mCyp2d22 NM_019823.4 
Forward: 5’- GGGCCTTTGTTACCATGTTGG -3’ 
Reverse: 5’- TACTCGGCGCTGCACATCTG -3’ 
mPxr NM_010936.3 
Forward: 5’- GGGATAGGGTTACAGCACGA -3’ 
Reverse: 5’- TCTGAAAAACCCCTTGCATC -3’ 
mCatalase NM_009804.2 
Forward: 5’- CACTGACGAGATGGCACACT-3’ 
Reverse: 5’- CACTGACGACGAGATGGCACACT-3’ 
Sod2 NM_013671.3 
Forward: 5’- TCTGTGGGAGTCCAAGGTTC-3’ 
Reverse: 5’- TAAGGCCTGTTGTTCCTTGC-3’ 
mGst-α NM_008181.3 
Forward: 5’- GCAGGGGTGGAGTTTGAAGA-3’ 
Reverse: 5’- TCTCTTTGGTCTGGGGGACA-3’ 
mGst-mu NM_008183.3 
Forward: 5’- TTCCCAATCTGCCCTACTTG-3’ 
Reverse: 5’- TGCCATAGCCTGGTTCTCC-3’ 
mGst-pi NM_013541.1 
Forward: 5’- TGCCACCATACACCATTGTC-3’ 
Reverse: 5’- CCAGCCTTGCATCCAGGTAT-3’ 
hPXR NM_003889.3 
Reverse: 5’- ACTCCCCTCACCTGCCATAA -3’ 
Reverse: 5’- CTCTTGGACTGCTTGGTGGT -3’ 
hCYP3A4 NM_017460.5 
Forward: 5’-GTCTTTGGGGCCTACAGCAT -3’ 
Reverse: 5’- GGGATGAGGAATGGAAAGACTGTT -3’ 
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Table 2. Oligonucleotide sequences of primers used for genotyping 
Gene Name Sequences 
hPXR 
Forward: 5’-GCA CCT GCT GCT AGG GAA TA-3’ 
Reverse: 5’-CTC CAT TGC CCC TCC TAA GT-3’ 
mPXR 
Forward: 5’-CTG GTC ATC ACT GTT GCT GTA CCA-3’ 
Reverse-1: 5’- GCA GCA TAG GAC AAG TTA TTC TAG AG -3’ 
Reverse-2: 5’-CTA AAG CGC ATG CTC CAG ACT GC -3’ 
FABP promoter 
(FABP-VP-PXR) 
Forward: 5′-CCATCGATAATTCTCAGAATACAAAACAGT-3′ 
Reverse: 5′-CCCAAGCTTCTGACCACAACAGCTCTGTCTGC-3′ 
mCyp3a11 
Forward: 5’-GGTAGCTAGTATAGCAGAACC-3’ 
Reverse: 5’-GTACATACAGCTCAGAGCCTG-3’ 
Wild-type Cyp3a11 Forward: 5’-CCACCAAATTGACATGAGTCC-3’ 
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Appendix B  
Table 3. Antibody information 
Antigen Company Identifier Application* Dilution 
4-HNE Abcam Ab48506 IHC/WB 1:25/1:200 
8-OHdG Abcam Ab48508 IF 1:200 
Cyp2b10 Abcam Ab9916 WB 1:200 
Cyp3a11/CYP3A4 
Obtained from Dr. Frank J. Gonzalez 
(National Cancer Institute, NIH) 
WB 1:200 
MPO Abcam AB_9353 IHC 1:25 
EST Abcam  AB_197674 IF 1:100 
Cyanine 5 conjugated 
donkey anti-rabbit 
polyclonal antibody 
MilliporeSigma AP182SA6MI IF 1:500 
Cyanine 3 conjugated 
donkey anti-mouse 
polyclonal antibody 
MilliporeSigma AP192C IF 1:500 
DAPI-Fluoromount-
G 
Southern Biotech 0100-20 IF - 
SULT1E1 Proteintech 12522-1-AP WB 1:200 
β-actin Sigma-Aldrich A1978 WB 1:5000 
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anti-rabbit antibody 
Cell Signaling 
Technology 
7074S WB 1:5000 
anti-mouse antibody 
Cell Signaling 
Technology 
7076S WB 1:5000 
anti-CD45 buv395 BD Biosciences 564279 Flow 1:100 
anti-CD11b-APC Biolegend 101212 Flow 1:100 
anti-Gr-1-PE Biolegend 108407 Flow 1:100 
anti-CXCR2-FITC Biolegend 149309 Flow 1:100 
*: WB, Western blot; IF, Immunofluorescence; IHC, Immunohistochemistry; Flow, Flow cytometry. 
 
 94 
Bibliography 
Abel RM and Reis RL (1971) Intravenous diazepam for sedation following cardiac operations: 
clinical and hemodynamic assessments. Anesth Analg 50:244-248. 
Albrethsen J, Miller LM, Novikoff PM, and Angeletti RH (2011) Gel-based proteomics of liver 
cancer progression in rat. Biochim Biophys Acta 1814:1367-1376. 
Anderson JE and Blaschke TF (1986) Ketoconazole inhibits cyclosporine metabolism in vivo in 
mice. J Pharmacol Exp Ther 236:671-674. 
Barbosa ACS, Feng Y, Yu C, Huang M, and Xie W (2019) Estrogen sulfotransferase in the 
metabolism of estrogenic drugs and in the pathogenesis of diseases. Expert Opin Drug 
Metab Toxicol 15:329-339. 
Bi Y, Shi X, Zhu J, Guan X, Garbacz WG, Huang Y, Gao L, Yan J, Xu M, Ren S, Ren S, Liu Y, 
Ma X, Li S, and Xie W (2018) Regulation of Cholesterol Sulfotransferase SULT2B1b by 
Hepatocyte Nuclear Factor 4alpha Constitutes a Negative Feedback Control of Hepatic 
Gluconeogenesis. Mol Cell Biol 38. 
Bjerregaard-Olesen C, Bossi R, Bech BH, and Bonefeld-Jorgensen EC (2015) Extraction of 
perfluorinated alkyl acids from human serum for determination of the combined 
xenoestrogenic transactivity: a method development. Chemosphere 129:232-238. 
Blumberg B, Sabbagh W, Jr., Juguilon H, Bolado J, Jr., van Meter CM, Ong ES, and Evans RM 
(1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-
3205. 
 95 
Bradley PP, Priebat DA, Christensen RD, and Rothstein G (1982) Measurement of cutaneous 
inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 
78:206-209. 
Breithaupt-Faloppa AC, Thais Fantozzi E, Romero DC, Rodrigues Ada S, de Sousa PT, Lino Dos 
Santos Franco A, Oliveira-Filho RM, Boris Vargaftig B, and Tavares de Lima W (2014) 
Acute effects of estradiol on lung inflammation due to intestinal ischemic insult in male 
rats. Shock 41:208-213. 
Bullard DC, Qin L, Lorenzo I, Quinlin WM, Doyle NA, Bosse R, Vestweber D, Doerschuk CM, 
and Beaudet AL (1995) P-selectin/ICAM-1 double mutant mice: acute emigration of 
neutrophils into the peritoneum is completely absent but is normal into pulmonary alveoli. 
J Clin Invest 95:1782-1788. 
Casa AJ, Hochbaum D, Sreekumar S, Oesterreich S, and Lee AV (2015) The estrogen receptor 
alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the 
receptor. Mol Cell Endocrinol 415:76-86. 
Chai X, Guo Y, Jiang M, Hu B, Li Z, Fan J, Deng M, Billiar TR, Kucera HR, Gaikwad NW, Xu 
M, Lu P, Yan J, Fu H, Liu Y, Yu L, Huang M, Zeng S, and Xie W (2015) Oestrogen 
sulfotransferase ablation sensitizes mice to sepsis. Nat Commun 6:7979. 
Dai F, Lee H, Zhang Y, Zhuang L, Yao H, Xi Y, Xiao ZD, You MJ, Li W, Su X, and Gan B (2017) 
BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress 
response. Proc Natl Acad Sci U S A 114:3192-3197. 
Deroo BJ, Hewitt SC, Collins JB, Grissom SF, Hamilton KJ, and Korach KS (2009) Profile of 
estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model. Mol 
Reprod Dev 76:733-750. 
 96 
Ding X, Jin S, Tong Y, Jiang X, Chen Z, Mei S, Zhang L, Billiar TR, and Li Q (2017) TLR4 
signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury. 
Sci Rep 7:34278. 
Dooley TP, Haldeman-Cahill R, Joiner J, and Wilborn TW (2000) Expression profiling of human 
sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. 
Biochem Biophys Res Commun 277:236-245. 
Dubaisi S, Caruso JA, Gaedigk R, Vyhlidal CA, Smith PC, Hines RN, Kocarek TA, and Runge-
Morris M (2019) Developmental Expression of the Cytosolic Sulfotransferases in Human 
Liver. Drug Metab Dispos 47:592-600. 
Eash KJ, Greenbaum AM, Gopalan PK, and Link DC (2010) CXCR2 and CXCR4 antagonistically 
regulate neutrophil trafficking from murine bone marrow. J Clin Invest 120:2423-2431. 
Edagawa M, Kawauchi J, Hirata M, Goshima H, Inoue M, Okamoto T, Murakami A, Maehara Y, 
and Kitajima S (2014) Role of activating transcription factor 3 (ATF3) in endoplasmic 
reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated 
apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J 
Biol Chem 289:21544-21561. 
Edmonds RD, Vodovotz Y, Lagoa C, Dutta-Moscato J, Yang Y, Fink MP, Levy RM, Prince JM, 
Kaczorowski DJ, Tseng GC, and Billiar TR (2011) Transcriptomic response of murine 
liver to severe injury and hemorrhagic shock: a dual-platform microarray analysis. Physiol 
Genomics 43:1170-1183. 
Falany CN (1991) Molecular enzymology of human liver cytosolic sulfotransferases. Trends 
Pharmacol Sci 12:255-259. 
 97 
Falany CN, He D, Li L, Falany JL, Wilborn TW, Kocarek TA, and Runge-Morris M (2009) 
Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic 
activity in cystic fibrosis (CF). J Steroid Biochem Mol Biol 114:113-119. 
Fang JL, Wu Y, Gamboa da Costa G, Chen S, Chitranshi P, and Beland FA (2016) Human 
Sulfotransferases Enhance the Cytotoxicity of Tolvaptan. Toxicol Sci 150:27-39. 
Fang WB, Lofwall MR, Walsh SL, and Moody DE (2013) Determination of oxycodone, 
noroxycodone and oxymorphone by high-performance liquid chromatography-
electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro 
applications. J Anal Toxicol 37:337-344. 
Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, Grail D, Ernst M, Jones 
SA, Topley N, and Jenkins BJ (2008) IL-6 regulates neutrophil trafficking during acute 
inflammation via STAT3. J Immunol 181:2189-2195. 
Frink M, Pape HC, van Griensven M, Krettek C, Chaudry IH, and Hildebrand F (2007) Influence 
of sex and age on mods and cytokines after multiple injuries. Shock 27:151-156. 
Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME 
(2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-
22. 
Gao J, He J, Shi X, Stefanovic-Racic M, Xu M, O'Doherty RM, Garcia-Ocana A, and Xie W 
(2012) Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes. 
Diabetes 61:1543-1551. 
Garbacz WG, Jiang M, Xu M, Yamauchi J, Dong HH, and Xie W (2017) Sex- and Tissue-Specific 
Role of Estrogen Sulfotransferase in Energy Homeostasis and Insulin Sensitivity. 
Endocrinology 158:4093-4104. 
 98 
Glatt H, Boeing H, Engelke CE, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, and Meinl 
W (2001) Human cytosolic sulphotransferases: genetics, characteristics, toxicological 
aspects. Mutat Res 482:27-40. 
Gong H, Singh SV, Singh SP, Mu Y, Lee JH, Saini SP, Toma D, Ren S, Kagan VE, Day BW, 
Zimniak P, and Xie W (2006) Orphan nuclear receptor pregnane X receptor sensitizes 
oxidative stress responses in transgenic mice and cancerous cells. Mol Endocrinol 20:279-
290. 
Gorska M, Wyszkowska RM, Kuban-Jankowska A, and Wozniak M (2016) Impact of Apparent 
Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-
Methoxyestradiol. Anticancer Res 36:2217-2226. 
Grinstein-Nadler E and Bottoms GD (1976) Dexamethasone treatment during hemorrhagic shock: 
changes in extracellular fluid volume and cell membrane transport. Am J Vet Res 37:1337-
1343. 
Guo Y, Hu B, Huang H, Tsung A, Gaikwad NW, Xu M, Jiang M, Ren S, Fan J, Billiar TR, Huang 
M, and Xie W (2015) Estrogen Sulfotransferase Is an Oxidative Stress-responsive Gene 
That Gender-specifically Affects Liver Ischemia/Reperfusion Injury. J Biol Chem 
290:14754-14764. 
Hall JM, Couse JF, and Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen 
receptor signaling. J Biol Chem 276:36869-36872. 
Hamidi SA, Dickman KG, Berisha H, and Said SI (2011) 17beta-estradiol protects the lung against 
acute injury: possible mediation by vasoactive intestinal polypeptide. Endocrinology 
152:4729-4737. 
 99 
Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, and Cherrington 
NJ (2013) Altered UDP-glucuronosyltransferase and sulfotransferase expression and 
function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab 
Dispos 41:554-561. 
He D, Wilborn TW, Falany JL, Li L, and Falany CN (2008) Repression of CFTR activity in human 
MMNK-1 cholangiocytes induces sulfotransferase 1E1 expression in co-cultured HepG2 
hepatocytes. Biochim Biophys Acta 1783:2391-2397. 
He Z and Simon HU (2013) Autophagy protects from liver injury. Cell Death Differ 20:850-851. 
Herrero J, Muffato M, Beal K, Fitzgerald S, Gordon L, Pignatelli M, Vilella AJ, Searle SM, Amode 
R, Brent S, Spooner W, Kulesha E, Yates A, and Flicek P (2016) Ensembl comparative 
genomics resources. Database (Oxford) 2016. 
Hrycay EG and Bandiera SM (2015) Involvement of Cytochrome P450 in Reactive Oxygen 
Species Formation and Cancer. Adv Pharmacol 74:35-84. 
Huang J, Bathena SP, Tong J, Roth M, Hagenbuch B, and Alnouti Y (2010) Kinetic analysis of 
bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). 
Xenobiotica 40:184-194. 
Jaeschke H (2011) Reactive oxygen and mechanisms of inflammatory liver injury: Present 
concepts. J Gastroenterol Hepatol 26 Suppl 1:173-179. 
Jancova P, Anzenbacher P, and Anzenbacherova E (2010) Phase II drug metabolizing enzymes. 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103-116. 
Jhingran A, Kasahara S, and Hohl TM (2016) Flow Cytometry of Lung and Bronchoalveolar 
Lavage Fluid Cells from Mice Challenged with Fluorescent Aspergillus Reporter (FLARE) 
Conidia. Bio Protoc 6. 
 100 
Kauffman FC (2004) Sulfonation in pharmacology and toxicology. Drug Metab Rev 36:823-843. 
Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, 
Willson TM, Zetterstrom RH, Perlmann T, and Lehmann JM (1998) An orphan nuclear 
receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82. 
Kohut LK, Darwiche SS, Brumfield JM, Frank AM, and Billiar TR (2011) Fixed volume or fixed 
pressure: a murine model of hemorrhagic shock. J Vis Exp. 
Krattinger R, Bostrom A, Lee SML, Thasler WE, Schioth HB, Kullak-Ublick GA, and Mwinyi J 
(2016) Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes 
involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci 156:47-56. 
Krug EG, Sharma GK, and Lozano R (2000) The global burden of injuries. Am J Public Health 
90:523-526. 
Lasarte S, Samaniego R, Salinas-Munoz L, Guia-Gonzalez MA, Weiss LA, Mercader E, Ceballos-
Garcia E, Navarro-Gonzalez T, Moreno-Ochoa L, Perez-Millan F, Pion M, Sanchez-
Mateos P, Hidalgo A, Munoz-Fernandez MA, and Relloso M (2016) Sex Hormones 
Coordinate Neutrophil Immunity in the Vagina by Controlling Chemokine Gradients. J 
Infect Dis 213:476-484. 
Lee SR, Lee SY, Kim SY, Ryu SY, Park BK, and Hong EJ (2017) Hydroxylation and sulfation of 
sex steroid hormones in inflammatory liver. J Biomed Res 31:437-444. 
Lei ZB, Fu XJ, Lu ZT, Wang BC, Liu XL, and You NZ (2003) Effect of estradiol on chemokine 
receptor CXCR2 expression in rats: implications for atherosclerosis. Acta Pharmacol Sin 
24:670-674. 
 101 
Li J, Oberly PJ, Poloyac SM, and Gibbs RB (2016) A microsomal based method to detect 
aromatase activity in different brain regions of the rat using ultra performance liquid 
chromatography-mass spectrometry. J Steroid Biochem Mol Biol 163:113-120. 
Li L and Falany CN (2007) Elevated hepatic SULT1E1 activity in mouse models of cystic fibrosis 
alters the regulation of estrogen responsive proteins. J Cyst Fibros 6:23-30. 
Li Y, Xiang M, Yuan Y, Xiao G, Zhang J, Jiang Y, Vodovotz Y, Billiar TR, Wilson MA, and Fan 
J (2009) Hemorrhagic shock augments lung endothelial cell activation: role of temporal 
alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol 297:R1670-1680. 
Lin W, Wang YM, Chai SC, Lv L, Zheng J, Wu J, Zhang Q, Wang YD, Griffin PR, and Chen T 
(2017) SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 8:741. 
Liu Y, Yuan Y, Li Y, Zhang J, Xiao G, Vodovotz Y, Billiar TR, Wilson MA, and Fan J (2009) 
Interacting neuroendocrine and innate and acquired immune pathways regulate neutrophil 
mobilization from bone marrow following hemorrhagic shock. J Immunol 182:572-580. 
Logsdon AF, Lucke-Wold BP, Nguyen L, Matsumoto RR, Turner RC, Rosen CL, and Huber JD 
(2016) Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior 
in a rodent model of traumatic brain injury. Brain Res 1643:140-151. 
Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, and Gonzalez FJ (2008) A double 
transgenic mouse model expressing human pregnane X receptor and cytochrome P450 
3A4. Drug Metab Dispos 36:2506-2512. 
Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, and Rankin SM (2003) 
Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the 
bone marrow and their return following senescence. Immunity 19:583-593. 
 102 
Matsubara T, Prough RA, Burke MD, and Estabrook RW (1974) The preparation of microsomal 
fractions of rodent respiratory tract and their characterization. Cancer Res 34:2196-2203. 
Matsushita N, Hassanein MT, Martinez-Clemente M, Lazaro R, French SW, Xie W, Lai K, Karin 
M, and Tsukamoto H (2017) Gender difference in NASH susceptibility: Roles of 
hepatocyte Ikkbeta and Sult1e1. PLoS One 12:e0181052. 
Matute-Bello G, Frevert CW, and Martin TR (2008) Animal models of acute lung injury. Am J 
Physiol Lung Cell Mol Physiol 295:L379-399. 
McDonald KA, Huang H, Tohme S, Loughran P, Ferrero K, Billiar T, and Tsung A (2015) Toll-
like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and 
reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) 
signaling. Mol Med 20:639-648. 
Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O'Keefe GE, Cohen MJ, 
Moldawer LL, Tompkins RG, Maier RV, Inflammation, and the Host Response to Injury 
Collaborative Research P (2012) The changing pattern and implications of multiple organ 
failure after blunt injury with hemorrhagic shock. Crit Care Med 40:1129-1135. 
Miyoshi T, Otsuka F, and Shimasaki S (2013) GRK-6 mediates FSH action synergistically 
enhanced by estrogen and the oocyte in rat granulosa cells. Biochem Biophys Res Commun 
434:401-406. 
Mueller JW, Gilligan LC, Idkowiak J, Arlt W, and Foster PA (2015) The Regulation of Steroid 
Action by Sulfation and Desulfation. Endocr Rev 36:526-563. 
Mueller JW, Idkowiak J, Gesteira TF, Vallet C, Hardman R, van den Boom J, Dhir V, Knauer SK, 
Rosta E, and Arlt W (2018) Human DHEA sulfation requires direct interaction between 
PAPS synthase 2 and DHEA sulfotransferase SULT2A1. J Biol Chem 293:9724-9735. 
 103 
Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong 
DC, Zeillinger R, and Thalhammer T (2017) Clinical significance of the estrogen-
modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian 
cancer. Oncol Lett 13:4047-4054. 
Negishi M, Pedersen LG, Petrotchenko E, Shevtsov S, Gorokhov A, Kakuta Y, and Pedersen LC 
(2001) Structure and function of sulfotransferases. Arch Biochem Biophys 390:149-157. 
Pasqualini JR (2009) Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad 
Sci 1155:88-98. 
Puntarulo S and Cederbaum AI (1998) Production of reactive oxygen species by microsomes 
enriched in specific human cytochrome P450 enzymes. Free Radic Biol Med 24:1324-
1330. 
Qian YM, Sun XJ, Tong MH, Li XP, Richa J, and Song WC (2001) Targeted disruption of the 
mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine 
and paracrine estrogen regulation. Endocrinology 142:5342-5350. 
Raftogianis RB, Wood TC, and Weinshilboum RM (1999) Human phenol sulfotransferases 
SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver 
genotype-phenotype correlations. Biochem Pharmacol 58:605-616. 
Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A, and Richardson RM (2012) The 
chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor 
kinases to mediate and regulate leukocyte functions. J Immunol 189:2824-2832. 
Reinen J and Vermeulen NP (2015) Biotransformation of endocrine disrupting compounds by 
selected phase I and phase II enzymes--formation of estrogenic and chemically reactive 
metabolites by cytochromes P450 and sulfotransferases. Curr Med Chem 22:500-527. 
 104 
Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009) Quantitative evaluation of the 
expression and activity of five major sulfotransferases (SULTs) in human tissues: the 
SULT "pie". Drug Metab Dispos 37:2255-2261. 
Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, and Hudson LD 
(2005) Incidence and outcomes of acute lung injury. N Engl J Med 353:1685-1693. 
Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, 
Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Jr., Fatkenheuer G, Gunthard HF, 
Molina JM, Jacobsen DM, and Volberding PA (2018) Antiretroviral Drugs for Treatment 
and Prevention of HIV Infection in Adults: 2018 Recommendations of the International 
Antiviral Society-USA Panel. JAMA 320:379-396. 
Saeki Y, Sakakibara Y, Araki Y, Yanagisawa K, Suiko M, Nakajima H, and Liu MC (1998) 
Molecular cloning, expression, and characterization of a novel mouse liver SULT1B1 
sulfotransferase. J Biochem 124:55-64. 
Shiels SM, Tennent DJ, and Wenke JC (2018) Topical Rifampin Powder for Orthopaedic Trauma 
Part I: Rifampin powder reduces recalcitrant infection in a delayed treatment 
musculoskeletal trauma model. J Orthop Res. 
Sinreih M, Knific T, Anko M, Hevir N, Vouk K, Jerin A, Frkovic Grazio S, and Rizner TL (2017) 
The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial 
Cancer. Front Pharmacol 8:368. 
Song WC (2001) Biochemistry and reproductive endocrinology of estrogen sulfotransferase. Ann 
N Y Acad Sci 948:43-50. 
Sperry JL, Friese RS, Frankel HL, West MA, Cuschieri J, Moore EE, Harbrecht BG, Peitzman 
AB, Billiar TR, Maier RV, Remick DG, Minei JP, Inflammation, and the Host Response 
 105 
to Injury I (2008) Male gender is associated with excessive IL-6 expression following 
severe injury. J Trauma 64:572-578; discussion 578-579. 
Sperry JL, Vodovotz Y, Ferrell RE, Namas R, Chai YM, Feng QM, Jia WP, Forsythe RM, 
Peitzman AB, and Billiar TR (2012) Racial disparities and sex-based outcomes differences 
after severe injury. J Am Coll Surg 214:973-980. 
Staren ED and Omer S (2004) Hormone replacement therapy in postmenopausal women. Am J 
Surg 188:136-149. 
Strott CA (2002) Sulfonation and molecular action. Endocr Rev 23:703-732. 
Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, and Cejalvo D (1993) Neutrophil infiltration as an 
important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and 
cyclosporine. Transplantation 55:1265-1272. 
Svetlov SI, Xiang Y, Oli MW, Foley DP, Huang G, Hayes RL, Ottens AK, and Wang KK (2006) 
Identification and preliminary validation of novel biomarkers of acute hepatic 
ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches. 
Biomarkers 11:355-369. 
Swamydas M and Lionakis MS (2013) Isolation, purification and labeling of mouse bone marrow 
neutrophils for functional studies and adoptive transfer experiments. J Vis Exp:e50586. 
Swamydas M, Luo Y, Dorf ME, and Lionakis MS (2015) Isolation of Mouse Neutrophils. Curr 
Protoc Immunol 110:3 20 21-23 20 15. 
Tien YC, Liu K, Pope C, Wang P, Ma X, and Zhong XB (2015) Dose of Phenobarbital and Age 
of Treatment at Early Life are Two Key Factors for the Persistent Induction of Cytochrome 
P450 Enzymes in Adult Mouse Liver. Drug Metab Dispos 43:1938-1945. 
 106 
Tjalkens RB, Cook LW, and Petersen DR (1999) Formation and export of the glutathione 
conjugate of 4-hydroxy-2, 3-E-nonenal (4-HNE) in hepatoma cells. Arch Biochem Biophys 
361:113-119. 
Toklu HZ and Tumer N (2015) Oxidative Stress, Brain Edema, Blood-Brain Barrier Permeability, 
and Autonomic Dysfunction from Traumatic Brain Injury, in: Brain Neurotrauma: 
Molecular, Neuropsychological, and Rehabilitation Aspects (Kobeissy FH ed), Boca Raton 
(FL). 
Tsai YF, Yu HP, Chung PJ, Leu YL, Kuo LM, Chen CY, and Hwang TL (2015) Osthol attenuates 
neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of 
phosphodiesterase 4. Free Radic Biol Med 89:387-400. 
Tyas B, Marsh M, Oswald T, Refaie R, Molyneux C, and Reed M (2018) Antibiotic resistance 
profiles of deep surgical site infections in hip hemiarthroplasty; comparing low dose single 
antibiotic versus high dose dual antibiotic impregnated cement. J Bone Jt Infect 3:123-129. 
Valavanidis A, Vlachogianni T, and Fiotakis C (2009) 8-hydroxy-2' -deoxyguanosine (8-OHdG): 
A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ 
Carcinog Ecotoxicol Rev 27:120-139. 
van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song 
JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, and 
Schinkel AH (2007) Knockout of cytochrome P450 3A yields new mouse models for 
understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. 
Villar J, Sulemanji D, and Kacmarek RM (2014) The acute respiratory distress syndrome: 
incidence and mortality, has it changed? Curr Opin Crit Care 20:3-9. 
 107 
Wang D, Li Q, Favis R, Jadwin A, Chung H, Fu DJ, Savitz A, Gopal S, and Cohen N (2014) 
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic 
response. Pharmacogenomics 15:1557-1564. 
Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR, 
and Mani S (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its 
analogs. Clin Cancer Res 13:2488-2495. 
Wang LQ, Falany CN, and James MO (2004) Triclosan as a substrate and inhibitor of 3'-
phosphoadenosine 5'-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase 
in human liver fractions. Drug Metab Dispos 32:1162-1169. 
Wen Z, Fan L, Li Y, Zou Z, Scott MJ, Xiao G, Li S, Billiar TR, Wilson MA, Shi X, and Fan J 
(2014) Neutrophils counteract autophagy-mediated anti-inflammatory mechanisms in 
alveolar macrophage: role in posthemorrhagic shock acute lung inflammation. J Immunol 
193:4623-4633. 
Wetzel G, Relja B, Klarner A, Henrich D, Dehne N, Bruhne B, Lehnert M, and Marzi I (2014) 
Myeloid knockout of HIF-1 alpha does not markedly affect hemorrhage/resuscitation-
induced inflammation and hepatic injury. Mediators Inflamm 2014:930419. 
Willson TM and Kliewer SA (2002) PXR, CAR and drug metabolism. Nat Rev Drug Discov 
1:259-266. 
Win S, Min RW, Chen CQ, Zhang J, Chen Y, Li M, Suzuki A, Abdelmalek MF, Wang Y, Aghajan 
M, Aung FW, Diehl AM, Davis RJ, Than TA, and Kaplowitz N (2019) Expression of 
mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver 
injury. J Clin Invest. 
 108 
Xie C, Yan TM, Chen JM, Li XY, Zou J, Zhu LJ, Lu LL, Wang Y, Zhou FY, Liu ZQ, and Hu M 
(2017) LC-MS/MS quantification of sulfotransferases is better than conventional 
immunogenic methods in determining human liver SULT activities: implication in 
precision medicine. Sci Rep 7:3858. 
Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, 
Brunt EM, Guzelian PS, and Evans RM (2000a) Humanized xenobiotic response in mice 
expressing nuclear receptor SXR. Nature 406:435-439. 
Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, Guzelian PS, and Evans RM 
(2000b) Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR 
and CAR. Genes Dev 14:3014-3023. 
Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, Guo Y, Ma X, Fan J, Billiar TR, and Xie W (2019) 
Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver 
Injury. Hepatology. 
Xu J, Guardado J, Hoffman R, Xu H, Namas R, Vodovotz Y, Xu L, Ramadan M, Brown J, 
Turnquist HR, and Billiar TR (2017) IL33-mediated ILC2 activation and neutrophil IL5 
production in the lung response after severe trauma: A reverse translation study from a 
human cohort to a mouse trauma model. PLoS Med 14:e1002365. 
Xu Y, Lin X, Xu J, Jing H, Qin Y, and Li Y (2018) SULT1E1 inhibits cell proliferation and 
invasion by activating PPARgamma in breast cancer. J Cancer 9:1078-1087. 
Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, and Redinbo MR (2007) Crystal 
structure of the pregnane X receptor-estradiol complex provides insights into endobiotic 
recognition. Mol Endocrinol 21:1028-1038. 
 109 
Yan J and Xie W (2016) A brief history of the discovery of PXR and CAR as xenobiotic receptors. 
Acta Pharm Sin B 6:450-452. 
Yan M, Huo Y, Yin S, and Hu H (2018) Mechanisms of acetaminophen-induced liver injury and 
its implications for therapeutic interventions. Redox Biol 17:274-283. 
Yang KC, Zhou MJ, Sperry JL, Rong L, Zhu XG, Geng L, Wu W, Zhao G, Billiar TR, and Feng 
QM (2014) Significant sex-based outcome differences in severely injured Chinese trauma 
patients. Shock 42:11-15. 
Yetti H, Naito H, Yuan Y, Jia X, Hayashi Y, Tamada H, Kitamori K, Ikeda K, Yamori Y, and 
Nakajima T (2018) Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in 
female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet. PLoS One 13:e0192863. 
Younger JG, Sasaki N, Waite MD, Murray HN, Saleh EF, Ravage ZB, Hirschl RB, Ward PA, and 
Till GO (2001) Detrimental effects of complement activation in hemorrhagic shock. J Appl 
Physiol (1985) 90:441-446. 
Yu HP, Hsu JC, Hwang TL, Yen CH, and Lau YT (2008) Resveratrol attenuates hepatic injury 
after trauma-hemorrhage via estrogen receptor-related pathway. Shock 30:324-328. 
Yue W, Yager JD, Wang JP, Jupe ER, and Santen RJ (2013) Estrogen receptor-dependent and 
independent mechanisms of breast cancer carcinogenesis. Steroids 78:161-170. 
Zingarelli B, Caputi AP, and Di Rosa M (1994) Dexamethasone prevents vascular failure mediated 
by nitric oxide in hemorrhagic shock. Shock 2:210-215. 
Zolin SJ, Vodovotz Y, Forsythe RM, Rosengart MR, Namas R, Brown JB, Peitzman AP, Billiar 
TR, and Sperry JL (2015) The early evolving sex hormone environment is associated with 
significant outcome and inflammatory response differences after injury. J Trauma Acute 
Care Surg 78:451-457; discussion 457-458. 
 110 
Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y, Lu L, and Liu Z (2017) Dopamine-induced 
SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour 
Biol 39:1010428317719272. 
 
